7th congress of european association for clinical pharmacology and ...
7th congress of european association for clinical pharmacology and ...
7th congress of european association for clinical pharmacology and ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
7 TH CONGRESS OF<br />
EUROPEAN ASSOCIATION<br />
FOR CLINICAL PHARMACOLOGY<br />
AND THERAPEUTICS<br />
POZNAŃ, POLAND, JUNE 25-29, 2005<br />
New level <strong>of</strong> communication <strong>and</strong> collaboration between<br />
<strong>clinical</strong> pharmacologists in United Europe<br />
CONGRESS PROGRAME
Welcome elcome Address ddress<br />
The 7 th Congress <strong>of</strong> the European Association <strong>for</strong> Clinical Pharmacology <strong>and</strong> Therapeutics<br />
in Poznan is a new level <strong>of</strong> communication <strong>and</strong> collaboration between <strong>clinical</strong> pharmacologists<br />
in the United Europe. The papers which will be presented during the Congress will show<br />
new trends <strong>of</strong> therapy <strong>of</strong> major diseases, as well as explore new areas <strong>of</strong> therapeutics.<br />
We wish to express our deepest gratitude to all the participants who accepted our invitation<br />
<strong>and</strong> came to Poznan to in<strong>for</strong>m us about the results <strong>of</strong> their <strong>clinical</strong> observations <strong>and</strong><br />
therapeutic conclusions. They will be extremely important to all the participants <strong>and</strong> will enrich<br />
our knowledge.<br />
May I express my hope that all my Colleagues participating in the Congress will have a<br />
good time in our city.<br />
Alex<strong>and</strong>er Mrozikiewicz<br />
Congress President<br />
The The The The The 77<br />
77 <strong>7th</strong><br />
th th th th EACPTCongress EACPTCongress EACPTCongress EACPTCongress EACPTCongress will will will will will be be be be be held held held held held under under under under under the the the the the honorary honorary honorary honorary honorary patronage<br />
patronage<br />
patronage<br />
patronage<br />
patronage<br />
<strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> Aleks<strong>and</strong>er Aleks<strong>and</strong>er Aleks<strong>and</strong>er Aleks<strong>and</strong>er Aleks<strong>and</strong>er Kwaśniewski– Kwaśniewski– Kwaśniewski– Kwaśniewski– Kwaśniewski– the the the the the President President President President President <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> Republic Republic Republic Republic Republic <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> Pol<strong>and</strong> Pol<strong>and</strong> Pol<strong>and</strong> Pol<strong>and</strong> Pol<strong>and</strong><br />
HONORARY HONORARY HONORARY HONORARY HONORARY COMMITTEE<br />
COMMITTEE<br />
COMMITTEE<br />
COMMITTEE<br />
COMMITTEE<br />
Grzegorz Grzegorz H. H. Brêborowicz<br />
Brêborowicz<br />
President <strong>of</strong> Poznañ University <strong>of</strong> Medical Sciences<br />
Mons. Mons. Mons. Stanis³aw Stanis³aw G¹decki<br />
G¹decki<br />
Archbishop <strong>of</strong> Poznañ Metropoly<br />
Ryszard Ryszard Grobelny<br />
Grobelny<br />
President <strong>of</strong> Poznañ<br />
Andrzej Andrzej KK<br />
Koronkiewicz<br />
KK<br />
oronkiewicz<br />
President <strong>of</strong> Office <strong>for</strong> Registration <strong>of</strong> Medicinal Products, Medical Devices, <strong>and</strong> Biocidal Products<br />
W³odzimierz W³odzimierz K KKubiak<br />
K ubiak<br />
Chairman <strong>of</strong> The Association <strong>of</strong> Pharmaceutical Companies Representatives in Pol<strong>and</strong><br />
Andrzej Andrzej B. B. Legocki<br />
Legocki<br />
President <strong>of</strong> Polish Academy <strong>of</strong> Sciences<br />
Stefan Stefan Stefan Miko³ajczak<br />
Miko³ajczak<br />
Marshall <strong>of</strong> Wielkopolska Province<br />
Andrzej Andrzej Nowakowski<br />
Nowakowski<br />
Governor <strong>of</strong> Wielkopolska Province<br />
Bogdan Bogdan P PPoniedzia³ek<br />
P oniedzia³ek<br />
Director <strong>of</strong> Poznañ University <strong>of</strong> Medical Sciences<br />
Andrzej Andrzej Obrêbowski<br />
Obrêbowski<br />
Vice-President <strong>of</strong> Poznañ University <strong>of</strong> Medical Sciences<br />
Tadeusz adeusz Rychlewski<br />
Rychlewski<br />
President <strong>of</strong> Poznañ University <strong>of</strong> Physical Education<br />
Bogus³aw Bogus³aw Zalewski Zalewski<br />
Zalewski<br />
President <strong>of</strong> the Board <strong>of</strong> Poznañ International Fair<br />
– – –
7 TH CONGRESS OF EUROPEAN ASSOCIATION<br />
FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS<br />
Alex<strong>and</strong>er Alex<strong>and</strong>er Mrozikiewicz<br />
Mrozikiewicz<br />
Congress President<br />
Przemysław Przemysław M. M. M. Mrozikiewicz<br />
Mrozikiewicz<br />
Congress Executive Chairman<br />
INTERNATIONAL SCIENTIFIC COMMITTEE<br />
N. Boada, Spain<br />
NATIONAL SCIENTIFIC COMMITTEE<br />
K. Brosen, Denmark<br />
J. Alkiewicz, Poznañ<br />
I. Cascorbi, Germany<br />
T. Bobkiewicz-Koz³owska, Poznañ<br />
J. Cockcr<strong>of</strong>t, UK<br />
G.H. Brêborowicz, Poznañ<br />
K. Dalh<strong>of</strong>f, Denmark<br />
T. Chruœciel, Warszawa<br />
J. Desmeules, Switzerl<strong>and</strong><br />
A. Czarnecki, Warszawa/ London<br />
I. Francetic, Croatia<br />
S. Czekalski, Poznañ<br />
P. Gepetti, Italy<br />
A. Cz³onkowski, Warszawa<br />
J. Gulbinovic, Lithuania<br />
A. Danysz, Warszawa<br />
J. Kuhlmann, Germany<br />
K. Drews, Poznañ<br />
J. Martinkova, Czech Republic<br />
J. Drzewoski, £ódŸ<br />
N. Moore, France<br />
M. Furmanowa, Warszawa<br />
P.M. Mrozikiewicz, Pol<strong>and</strong><br />
B. Gawroñska-Szklarz, Szczecin<br />
M. Orme, UK<br />
K. G³owniak, Lublin<br />
A. Rane, Sweden<br />
J. Gryglewski, Kraków<br />
I. Roots, Germany<br />
Z. S. Herman, Katowice<br />
A. Sabo, Yugoslavia<br />
M. Jarosz, Warszawa<br />
J. Schellens, Netherl<strong>and</strong>s<br />
W. Karnafel, Warszawa<br />
C. Tulunay, Turkey<br />
E. Korman, Poznañ<br />
A. Vas, Hungary<br />
E. Kostka-Tr¹bka, Kraków<br />
G.P. Velo, Italy<br />
A. Mackiewicz, Poznañ<br />
P.M. Mrozikiewicz, Poznañ<br />
ORGANISING COMMITTEE<br />
E. Nowakowska, Poznañ<br />
P.M. Mrozikiewicz – Chairman<br />
A. Obrêbowski, Poznañ<br />
M. M¹kosa – Congress Secretary<br />
K. Orzechowska-Juzwenko, Wroc³aw<br />
D. Kie³czewska-Mrozikiewicz<br />
D. Pupek-Musialik, Poznañ<br />
A. Seremak-Mrozikiewicz<br />
W. Rewerski, Warszawa<br />
J. Bartkowiak-Wieczorek<br />
J. Sp³awiñski, Warszawa<br />
P. Miko³ajczak<br />
J. Szymura-Oleksiak, Kraków<br />
P. Niewiñski<br />
B. Tarchalska-Kryñska, Warszawa<br />
A. Krajewska-Patan<br />
A. Wiela-Chojeñska, Wroc³aw<br />
M. Szczupski<br />
B. Brokl-Stolarczyk<br />
J. Wójcicki, Szczecin<br />
D. Stolarczyk<br />
European Association <strong>for</strong> Clinical Pharmacology <strong>and</strong> Therapeutics cooperates with:<br />
European Drug Utilisation Research Group (EuroDURG)<br />
European Federation <strong>for</strong> Pharmaceutical Sciences (EUFEPS)<br />
European Network <strong>of</strong> Therapeutics Teachers (ENOTT)<br />
International Federation <strong>of</strong> Associations <strong>of</strong> Pharmaceutical Physicians (IFAPP)<br />
International Society <strong>of</strong> Pharmacovigilance (ISOP)<br />
International Society <strong>for</strong> Pharmacoeconomics & Outcomes Research (ISPOR)<br />
International Society <strong>for</strong> Pharmacoeconomics & Outcomes Research Polish Branch<br />
Polish Herbal Committee (PKZ)<br />
Congress Congress co-organiser: co-organiser: Poznań Poznań International International Fair<br />
Fair<br />
Organisation supported by Ministry <strong>of</strong> Scientific Research <strong>and</strong> In<strong>for</strong>mation Technology<br />
nr: 647/P/DBB/2005<br />
– – –
ART ART EXHIBITION<br />
EXHIBITION<br />
Krystyna Krystyna Głowniak<br />
Głowniak<br />
Krystyna G³owniak is a famous <strong>and</strong> appreciated painter. The art <strong>of</strong> Krystyna G³owniak was presented during many individual<br />
<strong>and</strong> joint exhibitions in Pol<strong>and</strong> <strong>and</strong> abroad <strong>and</strong> also accompanied many theatre festivals <strong>and</strong> symposiums.<br />
The art <strong>of</strong> Krystyna G³owniak will be exhibited during the 7TH EACPT Congress in Poznañ.<br />
Adam Adam Półtorak<br />
Półtorak<br />
Herbarium<br />
Herbarium<br />
Adam Pó³torak creates painting <strong>and</strong> drawing, he is especially fascinated with a graphic made in manufacture technique<br />
<strong>of</strong> copperplate. His art is inspired by plants which create the specific herbarium on his paintings.<br />
His exhibition Herbarium will be presented during the 7TH EACPT Congress.<br />
Piotr Piotr Hudemowicz,Łukasz Hudemowicz,Łukasz Szczepańczyk<br />
Szczepańczyk<br />
The The taste taste <strong>of</strong> <strong>of</strong> the the Champagne<br />
Champagne<br />
Barbara Barbara Kostecka-Houwalt Kostecka-Houwalt Mystic Mystic Mystic Paintigs<br />
Paintigs<br />
Ewa Mrozikiewicz First Paintings<br />
– – –
CONGRESS CONGRESS SCHEDULE<br />
SCHEDULE<br />
FRIDAY FRIDAY FRIDAY June June 24, 24, 2005<br />
2005<br />
9.00 - 17.00 11<br />
11<br />
CONGRES CONGRESS CONGRESS<br />
S OF OF OF POLISH POLISH HERBAL HERBAL COMMIT COMMITTEE<br />
COMMIT TEE<br />
11 TH CONGRES<br />
9.00 - 17.00 WORKSHOP - METHODOLOGY OF CLINICAL TRIALS<br />
page: page: 21<br />
21<br />
SATURDAY SATURDAY June June 25, 25, 2005 2005<br />
2005<br />
9.00 - 17.00 11<br />
11<br />
CONGRES CONGRESS CONGRESS<br />
S OF OF OF POLISH POLISH HERBAL HERBAL COMMIT COMMITTEE<br />
COMMIT TEE<br />
11 TH CONGRES<br />
9.00 - 16.30 WORKSHOP - METHODOLOGY OF CLINICAL TRIALS<br />
page: page: 21 21<br />
21<br />
16.00 - 18.00 In<strong>for</strong>mal Meeting on Drug In<strong>for</strong>mation Systems<br />
18.00 - 22.00 OPENING OPENING CEREMONY<br />
CEREMONY<br />
SUNDAY SUNDAY June June 26, 26, 26, 2005 2005<br />
2005<br />
9.00 - 11.15 Neurodegenerative Neurodegenerative diseases: diseases: F FFrom<br />
F rom Research Research to to Clinical Clinical applications<br />
applications<br />
page: page: 10<br />
10<br />
9.00 - 11.15 Drug Drug registration registration in in Europe Europe from from the the view view point point <strong>of</strong> <strong>of</strong> countries countries countries entering entering the the EU<br />
EU<br />
page: page: 10<br />
10<br />
9.00 - 11.15 Future uture uture development development in in <strong>clinical</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
<strong>pharmacology</strong><br />
page: page: 10<br />
10<br />
11.15 - 11.30 COFFEE COFFEE BREAK<br />
BREAK<br />
11.30 - 12.15 PLENARY PLENARY LECTURE<br />
LECTURE<br />
Ryszard Ryszard Gryglewski<br />
Gryglewski<br />
Pharmacology <strong>of</strong> vascular endothelium<br />
12.15 - 14.30 LUNCH<br />
LUNCH<br />
12:45 – 15:00 POLISH POLISH CPT CPT MEETING<br />
MEETING<br />
Drug Drug Drug safety safety safety assessment assessment assessment <strong>and</strong> <strong>and</strong> <strong>and</strong> risk risk risk management<br />
management<br />
management<br />
page:<br />
page:<br />
– – –<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
3 RD FLOOR FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. PAV. 14B<br />
14B<br />
3 RD FLOOR FLOOR<br />
FLOOR<br />
PAV. PAV. PAV. 14B<br />
14B<br />
2 ND FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
2 ND FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
3 RD FLOOR FLOOR<br />
FLOOR
CONGRESS CONGRESS CONGRESS SCHEDULE: SCHEDULE: SUNDAY, SUNDAY, JUNE JUNE 26, 26, 26, 2005 2005<br />
2005<br />
12.45 - 15.00 POSTER POSTER SESSIONS<br />
SESSIONS<br />
POSTER POSTER POSTER SES SESSION SES SESSION<br />
SION 1<br />
1<br />
Drug registration in Europe from the view point <strong>of</strong> countries entering the EU<br />
Quality indicators in therapeutics<br />
Translation <strong>of</strong> <strong>clinical</strong> trials to <strong>clinical</strong> practice <strong>and</strong> the need <strong>for</strong> GCP – consequences <strong>of</strong> EU law<br />
Education issues in CPT<br />
POSTER POSTER SES SESSION SES SION 2<br />
2<br />
Future development in <strong>clinical</strong> <strong>pharmacology</strong><br />
POSTER POSTER SES SESSION SES SION 3<br />
3<br />
Clinical <strong>pharmacology</strong> <strong>and</strong> herbal medicine<br />
POSTER POSTER SES SESSION SES SION 4<br />
4<br />
Therapeutic research in HIV & other viral diseases<br />
POSTER POSTER SES SESSION SES SION 5<br />
5<br />
Drug delivery<br />
15.00 - 17.15 Pharmacological Pharmacological prevention prevention <strong>of</strong> <strong>of</strong> vascular vascular diseases<br />
diseases<br />
page: page: 11<br />
11<br />
15.00 - 17.15 Clinical Clinical <strong>pharmacology</strong> <strong>pharmacology</strong> <strong>pharmacology</strong> <strong>and</strong> <strong>and</strong> <strong>and</strong> herbal herbal herbal medicine<br />
medicine<br />
page: page: 12<br />
12<br />
– – –<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL
MONDAY MONDAY June June 27, 27, 2005<br />
2005<br />
9.00 - 11.15 New New Approaches Approaches in in Cardiovascular Cardiovascular Diseases Diseases : : : Arterial Arterial Stiffness<br />
Stiffness<br />
page: page: 13<br />
13<br />
9.00 - 11.15 Translation ranslation <strong>of</strong> <strong>of</strong> <strong>clinical</strong> <strong>clinical</strong> <strong>clinical</strong> trials trials to to <strong>clinical</strong> <strong>clinical</strong> practice practice <strong>and</strong> <strong>and</strong> the the the need need<br />
need<br />
<strong>for</strong> <strong>for</strong> GCP GCP – – consequences consequences <strong>of</strong> <strong>of</strong> EU EU law<br />
law<br />
page: page: 13<br />
13<br />
9.00 - 11.15 Quality Quality Quality indicators indicators in in therapeutics<br />
therapeutics<br />
page: page: 13<br />
13<br />
11.15 - 11.30 COFFEE COFFEE BREAK<br />
BREAK<br />
11.30 - 12.15 PLENARY PLENARY LECTURE<br />
LECTURE<br />
12.15 - 14.30 LUNCH<br />
LUNCH<br />
Janos Janos Borvendég<br />
Borvendég<br />
The Ethical Problems <strong>of</strong> Clinical Trials in Vulnerable Populations<br />
page: page: 14<br />
14<br />
12.30 EACPT EACPT GENERAL GENERAL ASSEMBLY<br />
ASSEMBLY<br />
12.45-15.00 POLISH POLISH POLISH CPT CPT MEETING<br />
MEETING<br />
BIOTECHNOL<br />
BIOTECHNOLOGY BIOTECHNOL<br />
BIOTECHNOL OGY AND AND AND CLINICAL CLINICAL CLINICAL PHARMACOL<br />
PHARMACOLOGY<br />
PHARMACOL<br />
PHARMACOLOGY<br />
OGY<br />
page: page: page: 14<br />
14<br />
12.45 - 15.00 POSTER POSTER SESSIONS<br />
SESSIONS<br />
POSTER POSTER SES SESSION SES SION 6 6<br />
6<br />
New Approaches in Cardiovascular Diseases : Arterial Stiffness<br />
POSTER POSTER POSTER SES SES SESSION SES SES SION 7<br />
7<br />
Pharmacological prevention <strong>of</strong> vascular diseases<br />
POSTER POSTER SES SESSION SES SION 8<br />
8<br />
Neurodegenerative diseases: From Research to Clinical applications<br />
POSTER POSTER SES SESSION SES SION 9<br />
9<br />
Issues in the modern therapy <strong>of</strong> obesity<br />
POSTER POSTER SES SESSION SES SION 10<br />
10<br />
Drug utilisation as a tool in <strong>clinical</strong> <strong>pharmacology</strong><br />
POSTER POSTER SES SESSION SES SION 11<br />
11<br />
The wise use <strong>of</strong> drugs<br />
POSTER POSTER SES SESSION SES SION 12<br />
12<br />
Rheumatic diseases <strong>and</strong> pain<br />
15.00 - 17.15 Issues Issues in in the the modern modern therapy therapy <strong>of</strong> <strong>of</strong> obesity<br />
obesity<br />
page: page: 14<br />
14<br />
15.00 - 17.15 Drug Drug utilisation utilisation as as a a tool tool tool in in <strong>clinical</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
<strong>pharmacology</strong><br />
page: page: 15<br />
15<br />
18.00 EACPT EACPT EACPT EXECUTIVE EXECUTIVE COMMITTEE COMMITTEE MEETING<br />
MEETING<br />
– – –<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 14B<br />
14B<br />
2 ND FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR FLOOR<br />
FLOOR<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 15 15<br />
15<br />
VIP VIP CLUB<br />
CLUB
TUESDAY TUESDAY TUESDAY June June 28, 28, 2005 2005<br />
2005<br />
9.00 - 11.15 Rheumatic Rheumatic diseases diseases <strong>and</strong> <strong>and</strong> <strong>and</strong> pain<br />
pain<br />
page: page: 16<br />
16<br />
9.00 - 11.15 Pharmacoeconomics<br />
Pharmacoeconomics<br />
page: page: 16<br />
16<br />
9.00 - 11.15 Pharmacovigilance<br />
Pharmacovigilance<br />
page: page: page: 17<br />
17<br />
11.15 - 11.30 COFFEE COFFEE COFFEE BREAK<br />
BREAK<br />
11.30 - 12.15 PLENARY PLENARY LECTURE<br />
LECTURE<br />
12.15 - 14.30 LUNCH<br />
LUNCH<br />
Silvio Silvio Garratini<br />
Garratini<br />
Orphan drugs: only <strong>for</strong> rare diseases?<br />
page: page: 17<br />
17<br />
12.45 – 15.00 POLISH POLISH CPT CPT MEETING MEETING<br />
MEETING<br />
Antibiotics<br />
Antibiotics<br />
page: page: page: 21 21<br />
21<br />
12.30 EACPT EACPT COUNCIL COUNCIL MEMBERS MEMBERS MEETING<br />
MEETING<br />
12.45 - 15.00 POSTER POSTER SESSIONS<br />
SESSIONS<br />
POSTER POSTER SES SESSION SES SION 13<br />
13<br />
Pharmacovigilance<br />
POSTER POSTER SES SESSION SES SION 14<br />
14<br />
Pharmacoeconomics<br />
POSTER POSTER SES SESSION SES SION 15<br />
15<br />
Pharmacogenomics<br />
15.00 - 17.15 The The The wise wise use use <strong>of</strong> <strong>of</strong> drugs<br />
drugs<br />
page: page: page: 18<br />
18<br />
Pharmacogenomics<br />
Pharmacogenomics<br />
page: page: 18<br />
18<br />
20.00 - 23.00 GALA GALA DINNER<br />
DINNER<br />
– – –<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 14B<br />
14B<br />
2 ND FLOOR<br />
FLOOR<br />
PAV. PAV. 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. PAV. 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL
WEDNESDAY WEDNESDAY June June 29, 29, 2005<br />
2005<br />
9.00 - 11.15 Therapeutic Therapeutic research research in in HIV HIV & & other other viral viral diseases<br />
diseases<br />
page: page: 19<br />
19<br />
9.00 - 11.15 Education Education issues issues in in CPT<br />
CPT<br />
page: page: page: 19<br />
19<br />
9.00 - 11.15 Drug Drug delivery<br />
delivery<br />
page: page: page: 20<br />
20<br />
11.15 - 11.30 COFFEE COFFEE BREAK<br />
BREAK<br />
11.30 - 12.15 PLENARY PLENARY LECTURE<br />
LECTURE<br />
Jan Jan Jan Schellens Schellens<br />
Schellens<br />
Molecular based novel anti cancer therapy<br />
page: page: 20<br />
20<br />
12.15 - 12.45 CLOSING CLOSING CEREMONY<br />
CEREMONY<br />
12.45 – 15.00 SATTELITE SATTELITE SYMPOSIUM<br />
SYMPOSIUM<br />
SYMPOSIUM<br />
Clinical Pharmacology in Eastern Europe - the roles in teaching,<br />
research <strong>and</strong> health care delivery.<br />
page: page: 21<br />
21<br />
– – –<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 14B<br />
14B<br />
1 ST FLOOR<br />
FLOOR<br />
PAV. PAV. 14B<br />
14B<br />
2 ND FLOOR<br />
FLOOR<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL<br />
HALL<br />
PAV. PAV. PAV. 15 15<br />
15<br />
CONGRESS CONGRESS HALL HALL<br />
HALL
CONGRESS CONGRESS PROGRAMME<br />
PROGRAMME<br />
SUNDAY JUNE 26, 2005<br />
9.00 9.00 – – 11:15 11:15 NEURODEGENERATIVE DISEASES: FROM RESEARCH TO CLINICAL APPLICATIONS<br />
Chair Chair Anna Anna Cz³onkowska Cz³onkowska (Pol<strong>and</strong>)<br />
Adam Adam V VVas<br />
V as (Hungary)<br />
Speakers Speakers Anna Anna Cz³onkowska Cz³onkowska (Pol<strong>and</strong>)<br />
The role <strong>of</strong> inflammation in an experimental model <strong>of</strong> Parkinson’s disease<br />
Amos Amos K KKorczyn<br />
K orczyn (Israel)<br />
Prevention <strong>of</strong> the dementia epidemic<br />
Hans Hans Hans Mel<strong>and</strong>er Mel<strong>and</strong>er (Sweden)<br />
Does the evidence <strong>of</strong> <strong>clinical</strong> efficacy <strong>of</strong> drugs against Alzheimer’s disease motivate routine use?<br />
Adam Adam V VVas<br />
V as (Hungary)<br />
The possibilities <strong>of</strong> positron emission tomography in drug research <strong>and</strong> development:<br />
studies on vinpocetine, a neuroprotective drug<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Nowakowska Nowakowska E., E., K KKus<br />
K us K.,Czubak K.,Czubak K.,Czubak A AA.,<br />
A ., Florek Florek E.<br />
E.<br />
Effect <strong>of</strong> nicotine <strong>and</strong> olanzapine on cognitive functions in tobacco smoke non-exposed <strong>and</strong> exposed rats<br />
Slopien Slopien R., R., R., Meczekalski Meczekalski B., B., B., WW<br />
Warenik-Szymankiewicz WW<br />
arenik-Szymankiewicz A AA.<br />
A<br />
Serum galanin level in postmenopausal women with climacteric symptoms<br />
Mikolajczak Mikolajczak PL., PL., Okulicz Okulicz – – K KKozaryn<br />
K Kozaryn<br />
ozaryn I., I., T TTokarska<br />
T okarska M., M., Kaminska Kaminska Kaminska E., E., Szulc Szulc M.,<br />
M.,<br />
Bobkiewicz Bobkiewicz – – K KKozlowska<br />
K ozlowska T TT.<br />
T<br />
Multiple bacl<strong>of</strong>en <strong>and</strong> acamprosate administration effect on short-term memory <strong>of</strong> wistar rats<br />
9.00 9.00 – – 11:15 11:15 DRUG DRUG REGISTRATION REGISTRATION IN IN EUROPE EUROPE FROM FROM THE THE VIEW VIEW POINT POINT OF OF COUNTRIES COUNTRIES ENTERING ENTERING THE THE EU<br />
EU<br />
Chair Chair Daniel Daniel Brasseur Brasseur (Belgium)<br />
El¿bieta El¿bieta El¿bieta W WWojtasik<br />
W ojtasik (Pol<strong>and</strong>)<br />
Speakers Speakers Speakers Daniel Daniel Brasseur Brasseur (CHMP at EMEA)<br />
Vaccines, Clinical requirements, Quality <strong>of</strong> the documentation<br />
Aleks<strong>and</strong>er Aleks<strong>and</strong>er P PP.<br />
P . Mazurek Mazurek (Pol<strong>and</strong>)<br />
Registration in Pol<strong>and</strong>: toward 2008<br />
Muhittin Muhittin Bilgütay Bilgütay (Turkey)<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Kunicki unicki PK.<br />
PK.<br />
Bioequivalence criteria <strong>for</strong> generics <strong>of</strong> immunosuppressive drugs<br />
De De Mey Mey C., C., Gatchev Gatchev E. E.<br />
E.<br />
Global generics': issues resulting from lack <strong>of</strong> between-country bioequivalence <strong>of</strong> originator reference<br />
<strong>for</strong>mulations<br />
Sonne Sonne J., J., J., BregnhYj BregnhYj L., L., L., Thirstrup Thirstrup S., S., Kristensen Kristensen MB., MB., MB., Bjerrum Bjerrum L. L.<br />
L.<br />
A r<strong>and</strong>omised, controlled study to reduce inappropriate prescribing in elderly polypharmacy patients<br />
in primary care<br />
9.00 9.00 – – 11:15 11:15 11:15 FUTURE FUTURE DEVELOPMENT DEVELOPMENT IN IN CLINICAL CLINICAL PHARMACOLOGY<br />
PHARMACOLOGY<br />
Chair Chair Sir Sir Colin Colin Dollery Dollery (UK)<br />
Zbigniew Zbigniew Herman Herman (Pol<strong>and</strong>)<br />
Speakers Speakers Speakers Zbigniew Zbigniew Zbigniew Herman Herman (Pol<strong>and</strong>)<br />
Progress <strong>and</strong> Dilemma <strong>of</strong> Contemporary Clinical Pharmacology<br />
Sir Sir Colin Colin Colin Dollery Dollery (UK)<br />
Experimental medicine, CP <strong>and</strong> the delivery <strong>of</strong> medical care<br />
Malcolm Malcolm Law Law (UK)<br />
Polypills <strong>for</strong> poly-ills<br />
– – –
Bernard Bernard Bégaud Bégaud (France)<br />
Pharmacovigilance <strong>and</strong> pharmacoepidemiology in medical education <strong>for</strong> future<br />
Clinical Pharmacologists<br />
Mike Mike T TTrower/<br />
T rower/ Christine Christine de de Bouck Bouck (USA)<br />
Are transcripts <strong>of</strong> proteins the way ahead?<br />
Michael Michael Orme<br />
Orme<br />
The role <strong>of</strong> EACPT in the Development <strong>of</strong> Clinical Pharmacology in Europe<br />
Free Free<br />
Free<br />
communicommuni<br />
cations cations Lamparczyk Lamparczyk H., H., H., K KKonieczna<br />
K onieczna L., L., Chmielewska Chmielewska A<br />
A<br />
Sex drug interaction studies suported by modern statistical methods<br />
11:15 11:15 – – 11:30 11:30 COFFEE COFFEE BREAK<br />
BREAK<br />
PLENARY PLENARY LECTURE<br />
LECTURE<br />
11:30 11:30 – – 12:15 12:15 Ryszard Ryszard Gryglewski<br />
Gryglewski<br />
Pharmacology Pharmacology Pharmacology Pharmacology Pharmacology <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> vascular vascular vascular vascular vascular endothelium<br />
endothelium<br />
endothelium<br />
endothelium<br />
endothelium<br />
12:15 12:15 – – 12:45 12:45 LUNCH<br />
LUNCH<br />
12:45 12:45 – – 15:00 15:00 POSTER POSTER SESSIONS SESSIONS<br />
SESSIONS<br />
POSTER POSTER SESSION SESSION 1 1<br />
1<br />
Drug Drug registration registration in in Europe Europe from from the the view view point point point <strong>of</strong> <strong>of</strong> countries countries entering entering the the EU<br />
EU<br />
Quality Quality indicators indicators in in therapeutics<br />
therapeutics<br />
therapeutics<br />
Translation Translation Translation <strong>of</strong> <strong>of</strong> <strong>clinical</strong> <strong>clinical</strong> <strong>clinical</strong> trials trials to to <strong>clinical</strong> <strong>clinical</strong> practice practice <strong>and</strong> <strong>and</strong> the the need need <strong>for</strong> <strong>for</strong> GCP GCP – – – consequences consequences consequences <strong>of</strong> <strong>of</strong> EU EU law<br />
law<br />
Education Education issues issues in in CPT<br />
CPT<br />
POSTER POSTER SESSION SESSION 2<br />
2<br />
Future Future development development in in <strong>clinical</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
<strong>pharmacology</strong><br />
POSTER POSTER SESSION SESSION 3<br />
3<br />
Clinical Clinical <strong>pharmacology</strong> <strong>pharmacology</strong> <strong>and</strong> <strong>and</strong> herbal herbal medicine<br />
medicine<br />
POSTER POSTER SESSION SESSION 4<br />
4<br />
Therapeutic Therapeutic research research in in in hiv hiv hiv <strong>and</strong> <strong>and</strong> other other other viral viral viral diseases<br />
diseases<br />
POSTER POSTER SESSION SESSION 5<br />
5<br />
Drug Drug delivery<br />
delivery<br />
15:00 15:00 – – 17:15 17:15 PHARMACOLOGICAL PHARMACOLOGICAL PREVENTION PREVENTION OF OF VASCULAR VASCULAR DISEASES<br />
DISEASES<br />
Chair Chair Stephane Stephane Laurent Laurent (France)<br />
Ian Wilkinson (UK)<br />
Local<br />
Local<br />
coordinator coordinator Stefan Stefan Ch³opicki Ch³opicki (Pol<strong>and</strong>)<br />
Speakers Speakers Ian Ian W WWilkinson<br />
W ilkinson (UK)<br />
Diabetes a vascular disease: therapeutic opportunities<br />
Stéphane Stéphane Laurent Laurent (France)<br />
New or old antihypertensive medications<br />
John John Cockr<strong>of</strong>t Cockr<strong>of</strong>t (UK)<br />
Lipids<br />
James James Ritter Ritter Ritter (UK)<br />
Effects <strong>of</strong> cox inhibition on vascular disease<br />
– – –
Free<br />
Free<br />
communicommuni<br />
cations cations Grundmann Grundmann Grundmann M., M., Kacirova Kacirova I.<br />
I.<br />
The mistakes in combination therapy <strong>of</strong> resistant hypertension<br />
Gomez-Ontanon Gomez-Ontanon E., E., E., Herrera Herrera MA MA., MA ., Del Del Mar Mar García-Sáiz García-Sáiz M., M., M., Ramos Ramos Pérez Pérez B., B., Boada Boada JN.<br />
JN.<br />
Modifications in the effectiveness <strong>of</strong> antihypertensive drugs by the use <strong>of</strong> concomitant agents<br />
Harder Harder S., S., Graff Graff J., J., Misselwitz Misselwitz F FF.,<br />
FF<br />
., ., K KKubitza<br />
K ubitza D.<br />
D.<br />
Effects <strong>of</strong> the oral factor xa-inhibitor bay 59-7939 on platelet-induced thrombin generation<br />
Van an Ganse Ganse E., E., W WWalley<br />
W alley TT<br />
T., T ., FF<br />
Folino-gallo F olino-gallo P PP.,<br />
P ., La<strong>for</strong>est La<strong>for</strong>est L., L., Group Group Euro Euro Euro Med Med Stat Stat<br />
Stat<br />
Lipid lowering agents 1999-2003: comparison among <strong>european</strong> countries<br />
Okopien Okopien B., B., Huzarska Huzarska M., M., Belowski Belowski D., D., Madej Madej Madej AA<br />
A., AA<br />
., Herman Herman ZS<br />
ZS<br />
Fen<strong>of</strong>ibrate <strong>and</strong> atorvastatin decrease monocyte chemotactic protein 1 (mcp-1) plasma levels <strong>and</strong><br />
monocyte release in dyslipidaemic patients.<br />
15:00 15:00 – – 17:15 17:15 CLINICAL CLINICAL PHARMACOLOGY PHARMACOLOGY AND AND HERBAL HERBAL MEDICINE<br />
MEDICINE<br />
Chair Chair Przemys³aw Przemys³aw M. M. Mrozikiewicz Mrozikiewicz (Pol<strong>and</strong>)<br />
Ivar Ivar Roots Roots (Germany)<br />
Speakers Speakers Ivar Ivar Roots Roots (Germany)<br />
Interference <strong>of</strong> herbs with <strong>for</strong>eign compound-metabolizing enzymes <strong>and</strong> transporters – <strong>clinical</strong> <strong>and</strong><br />
in-vitro studies<br />
Max Max Max Pittler Pittler (UK)<br />
Assessing the safety <strong>of</strong> herbal medicines<br />
Mohammed Mohammed Mohammed FF<br />
Farah FF<br />
arah arah (Sweden)<br />
Key issues <strong>for</strong> herbal adverse drug reactions<br />
Veronica eronica Butterweck Butterweck (USA)<br />
Natural products as causes <strong>of</strong> drug interactions<br />
Bernhardt Bernhardt Klier Klier, Klier , Lothar Lothar Kabelitz Kabelitz (Germany)<br />
Toxic impurities in herbal drugs <strong>and</strong> their preparations<br />
Free Free<br />
Free<br />
communicommuni<br />
cations cations Samojlik Samojlik I., I., Bozin Bozin B., B., Djakovic Djakovic - - Svajcer Svajcer K.<br />
K.<br />
The influence <strong>of</strong> acute <strong>and</strong> chronic pretreatment with peppermint oil on drug effects in mice<br />
Calvo Calvo Calvo F FFerr<strong>and</strong>iz<br />
F err<strong>and</strong>iz A AA.,<br />
A ., T TTerleira<br />
TT<br />
erleira A AA.,<br />
A ., Martinez Martinez I., I., Lerebours Lerebours G., G., P PPortoles<br />
PP<br />
ortoles A AA.<br />
A<br />
Effect <strong>of</strong> hypericum per<strong>for</strong>atum on ivabradine pharmacokinetics in healthy volunteers<br />
Giannioti Giannioti K., K., P PPapalois<br />
P apalois A AA.,<br />
A ., Theocharis Theocharis S., S., Drakoulis Drakoulis N., N., Galanopoulou Galanopoulou P PP.<br />
P<br />
Additive preventive effect <strong>of</strong> silybinin <strong>and</strong> cimetidine against paracetamol-induced hepatotoxicity in<br />
rabbits<br />
– – –
Monday Monday June June June 27, 27, 2005<br />
2005<br />
9.00 9.00 – – 11:15 11:15 NEW NEW NEW APPROACHES APPROACHES IN IN CARDIOVASCULAR CARDIOVASCULAR DISEASES: DISEASES: ARTERIAL ARTERIAL ARTERIAL STIFFNESS STIFFNESS<br />
STIFFNESS<br />
Chair Chair John John Cockcr<strong>of</strong>t Cockcr<strong>of</strong>t (UK)<br />
El¿bieta El¿bieta K KKostka<br />
K ostkaostka-Tr¹bkaostka r¹bka (Pol<strong>and</strong>)<br />
Speakers Speakers John Cockcr<strong>of</strong>t (UK)<br />
Arterial stiffness as a risk factor <strong>for</strong> cardiovascular disease<br />
Stephane Stephane Laurent Laurent Laurent (France)<br />
Methods <strong>of</strong> assessing arterial stiffness in <strong>clinical</strong> practice<br />
Carmel Carmel McEniery McEniery (Australia)<br />
Factors regulating arterial stiffness<br />
Charalambos Charalambos Vlachopoulos Vlachopoulos (Greece)<br />
Aortic stiffness as a therapeutic target<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Mackenzie Mackenzie I., I., Maki-P Maki-Petaja Maki-P etaja K., K., Mceniery Mceniery C.M., C.M., Bao Bao YP YP., YP ., WW<br />
Wallace W allace S.,<br />
S.,<br />
Cheriyan Cheriyan J., J., J., Monteith Monteith S.,<br />
S.,<br />
Aldehyde dehydrogenase 2 <strong>and</strong> the bioactivation <strong>of</strong> glyceryl trinitrate in humans<br />
Golubev Golubev S., S., Mily Mily M.<br />
M.<br />
Circadian patterns <strong>of</strong> left ventricle per<strong>for</strong>mance <strong>and</strong> arterial compliance under nebivolol treatment<br />
determine its antihypertensive effect<br />
Magnusson Magnusson Magnusson MV MV., MV ., Bergstr<strong>and</strong> Bergstr<strong>and</strong> I.C., I.C., Björkman Björkman S., S., Heijl Heijl Heijl A AA.,<br />
A ., Roth Roth B., B., B., Höglund Höglund Höglund PP<br />
P. PP<br />
Pentoxifylline <strong>and</strong> its metabolites: effects on retinal blood flow in humans<br />
Paluch aluch Z.<br />
Z.<br />
Aspirin resistance in patients with cardiovascular <strong>and</strong> cerebrovascular diseases<br />
9.00 9.00 – – 11:15 11:15 TRANSLATION TRANSLATION OF OF CLINICAL CLINICAL CLINICAL TRIALS TRIALS TO TO CLINICAL CLINICAL CLINICAL PRACTICE PRACTICE PRACTICE AND AND THE THE THE NEED NEED FOR FOR FOR GCP GCP – –<br />
–<br />
CONSEQUENCES CONSEQUENCES OF OF EU EU LAW LAW<br />
LAW<br />
Symposium Symposium run run in in <strong>association</strong> <strong>association</strong> <strong>association</strong> with with IF IFAPP IF APP <strong>and</strong> <strong>and</strong> EFGCP<br />
EFGCP<br />
Chairmen Chairmen Francis rancis Crawley Crawley ( EFGCP - Belgium)<br />
Domenico Domenico Criscuolo Criscuolo (Italy)<br />
Speakers Speakers Kathrin Kathrin Laubacher Laubacher (Switzerl<strong>and</strong>)<br />
Clinical trials <strong>and</strong> GCP in Pol<strong>and</strong>: the Roche experience<br />
Gabriele Gabriele Schwarz Schwarz (Germany)<br />
GCP in Clinical Trials: Reliability <strong>of</strong> relevant data <strong>and</strong> the protection <strong>of</strong> subjects both present<br />
<strong>and</strong> future; A European-GCP-inspector’s perspective<br />
Francis rancis Crawley Crawley (EFGCP-Belgium)<br />
GCP in Clinical Trials as GCP in Patient Care: GCP linking Research <strong>and</strong> Patient Care<br />
9.00 9.00 – – 11:15 11:15 11:15 QUALITY QUALITY INDICATORS INDICATORS INDICATORS IN IN THERAPEUTICS<br />
THERAPEUTICS<br />
Chairmen Chairmen Ulf Ulf Bergman Bergman Bergman (Sweden)<br />
Andrzej Andrzej Cz³onkowski<br />
Cz³onkowski Cz³onkowski (Pol<strong>and</strong>)<br />
Speakers Speakers Morten Morten Andersen Andersen (Denmark)<br />
Validating prescribing quality indicators – how do we know that they measure quality?<br />
Vera era Vlahovic-P Vlahovic-Palcevski<br />
Vlahovic-P alcevski (Croatia)<br />
Use <strong>of</strong> quality indicators <strong>for</strong> antibiotic prescribing<br />
Ulf Ulf Ulf Bergman Bergman Bergman (Sweden)<br />
Use <strong>of</strong> voluntary adverse drug reaction reporting as a quality indicator“Lämbit Rägo (WHO)<br />
WHO indicators used to assess the quality <strong>of</strong> drug therapy at the national level<br />
– – –
Free<br />
Free<br />
communicommuni<br />
cations cations B. B. B. W WWettermark<br />
W ettermark<br />
Drug utilization 90%; using aggregate drug statistics <strong>for</strong> the quality assessment <strong>of</strong> prescribing 00443<br />
Fantino antino B., B., F FFantino<br />
F antino FF<br />
F., F ., Chretin Chretin S., S., VV<br />
Voirin VV<br />
oirin N., N., Blum Blum M., M., VV<br />
Van VV<br />
an Ganse Ganse E., E., La<strong>for</strong>est La<strong>for</strong>est L. L.<br />
L.<br />
Impact <strong>of</strong> a training program <strong>of</strong> general practitioners on their behaviour towards prescribing to elderly<br />
patients<br />
Erdeljic Erdeljic V VV.,<br />
V ., F FFrancetic<br />
F rancetic I., I., Makar Makar-Ausperger Makar -Ausperger K., K., Macolic Macolic Sarinic Sarinic V VV.,<br />
V ., Mercep Mercep I., I., Erceg Erceg D., D., Kalogjera Kalogjera N., N., Mrzljak Mrzljak A AA.<br />
A<br />
Quality <strong>of</strong> pain management in hospitalized patients<br />
11:15 11:15 – – 11:30 11:30 COFFEE COFFEE BREAK<br />
BREAK<br />
PLENARY PLENARY LECTURE<br />
LECTURE<br />
11:30 11:30 – – 12:15 12:15 Janos Janos Janos Borvendég<br />
Borvendég<br />
The The The The The ethical ethical ethical ethical ethical problems problems problems problems problems <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>of</strong> <strong>clinical</strong> <strong>clinical</strong> <strong>clinical</strong> <strong>clinical</strong> <strong>clinical</strong> trials trials trials trials trials in in in in in vulnerable vulnerable vulnerable vulnerable vulnerable populations<br />
populations<br />
populations<br />
populations<br />
populations<br />
12:15 12:15 – – 12:45 12:45 LUNCH<br />
LUNCH<br />
12:45 12:45 – – 15:00 15:00 POSTER POSTER SESSION<br />
SESSION<br />
POSTER POSTER POSTER SESSION SESSION SESSION 6<br />
6<br />
New New approaches approaches in in cardiovascular cardiovascular diseases diseases – – arterial arterial stiffness<br />
stiffness<br />
POSTER POSTER SESSION SESSION 7<br />
7<br />
Pharmacological Pharmacological Pharmacological prevention prevention <strong>of</strong> <strong>of</strong> vascular vascular vascular diseases<br />
diseases<br />
POSTER POSTER POSTER SESSION SESSION 8<br />
8<br />
Neurodegenerative Neurodegenerative diseases: diseases: From From Research Research to to to Clinical Clinical applications<br />
applications<br />
POSTER POSTER SESSION SESSION SESSION 9<br />
9<br />
Issues Issues in in modern modern modern therapy therapy <strong>of</strong> <strong>of</strong> obesity<br />
obesity<br />
POSTER POSTER SESSION SESSION 10 10<br />
10<br />
Drug Drug Drug utilization utilization as as a a tool tool in in <strong>clinical</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
<strong>pharmacology</strong><br />
POSTER POSTER SESSION SESSION SESSION 11<br />
11<br />
The The wise wise use use <strong>of</strong> <strong>of</strong> <strong>of</strong> drugs<br />
drugs<br />
POSTER POSTER SESSION SESSION 12<br />
12<br />
Rheumatic Rheumatic diseases diseases <strong>and</strong> <strong>and</strong> pain<br />
pain<br />
15:00 15:00 – – 17:15 17:15 ISSUES ISSUES IN IN THE THE MODERN MODERN THERAPY THERAPY OF OF OBESITY<br />
OBESITY<br />
Chairmen Chairmen Chairmen Gyula Gyula Gyula Gyenis Gyenis Gyenis (Hungary)<br />
Waldemar aldemar aldemar Karnafel Karnafel (Pol<strong>and</strong>)<br />
Speakers Speakers Gyula Gyula Gyenis Gyenis (Hungary)<br />
Epidemiology <strong>and</strong> cost <strong>of</strong> obesity in Europe<br />
Krzyszt<strong>of</strong> Krzyszt<strong>of</strong> Narkiewicz Narkiewicz (Pol<strong>and</strong>)<br />
Management <strong>of</strong> obese cardiac patients<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Stojiljkovic Stojiljkovic M.P M.P., M.P ., Lopes Lopes H.F H.F., H.F ., Mitchell Mitchell J.M., J.M., Morrow Morrow J.D., J.D., Goodfriend Goodfriend TT<br />
T.L., T .L., Egan Egan B.M.<br />
B.M.<br />
Influence <strong>of</strong> fatty acids on blood pressure in obese, hypertensive humans<br />
Zozulinska Zozulinska Zozulinska D. D.<br />
D.<br />
The role <strong>of</strong> inflammation in the pathogenesis <strong>of</strong> late diabetic complications<br />
Mrozikiewicz-Rakowska Mrozikiewicz-Rakowska B., B., Rakowski Rakowski PP<br />
P., PP<br />
., Karnafel Karnafel W WW.,<br />
W ., Pupek-Musialik Pupek-Musialik D.<br />
D.<br />
The influence <strong>of</strong> i/d angiotensin converting enzyme gene polymorphizm the presence <strong>of</strong> hypertension<br />
<strong>and</strong> lipid disorders in obese subjects?<br />
Meczekalski Meczekalski B., B., Slopien Slopien Slopien R., R., W WWarenik-Szymankiewicz<br />
W arenik-Szymankiewicz AA<br />
A. AA<br />
Neuropeptide y serum levels in young women with obesity<br />
– – –
15:00 15:00 – – 17:15 17:15 DRUG DRUG UTILISATION UTILISATION UTILISATION AS AS A A TOOL TOOL IN IN CLINICAL CLINICAL PHARMACOLOGY<br />
PHARMACOLOGY<br />
Symposium Symposium run run in in <strong>association</strong> <strong>association</strong> with with EURODURG<br />
EURODURG<br />
Chairmen Chairmen Chairmen Jolanta Jolanta Gulbinovic Gulbinovic (Lithuania)<br />
Robert Robert VV<br />
V<strong>and</strong>er VV<br />
<strong>and</strong>er Stichele Stichele (Belgium)<br />
Local<br />
Local<br />
coordinator coordinator Bogus³aw Bogus³aw Okopieñ Okopieñ (Pol<strong>and</strong>)<br />
Speakers Speakers Alan Alan Irs Irs (Estonia)<br />
Did the Eastern European Drug Utilisation monitoring traditions survive the transition?<br />
Jolanta Jolanta Gulbinovi Gulbinovic Gulbinovi (Lithuania)<br />
The role <strong>of</strong> the <strong>clinical</strong> pharmacologist in drug utilisation research <strong>and</strong> drug use evaluation<br />
activities in hospital<br />
Robert Robert V VV<strong>and</strong>er<br />
V <strong>and</strong>er Stichele Stichele (Belgium)<br />
The role <strong>of</strong> the <strong>clinical</strong> pharmacologist in drug utilisation research <strong>and</strong> drug use evaluation activities<br />
in ambulatory care<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Andersen Andersen SE., SE., Christensen Christensen HR.<br />
HR.<br />
Do hospital doctors impose excessive drug costs on primary health care?<br />
Trifiro rifiro G., G., Piacentini Piacentini N., N., T TTari<br />
TT<br />
ari M., M., Moretti Moretti S., S., Arcoraci Arcoraci V VV.<br />
V<br />
Statin-macrolide interaction risk: a population-based study throughout a general practice database<br />
Van an Schalkwyk Schalkwyk K., K., T TTruter<br />
T ruter I.<br />
I.<br />
Antidepressants in children <strong>and</strong> adolescents: a south african study<br />
– – –
Tuesday Tuesday June June June 28, 28, 2005<br />
2005<br />
9.00 9.00 – – 11:15 11:15 RHEUMATIC RHEUMATIC DISEASES DISEASES AND AND PAIN<br />
PAIN<br />
Chairmen Chairmen Józef Józef Drzewoski Drzewoski (Pol<strong>and</strong>)<br />
Cankat Cankat Cankat T TTulunay<br />
T ulunay (Turkey)<br />
Speakers Speakers Speakers Cankat Cankat Cankat T TTulunay<br />
T ulunay (Turkey)<br />
Selection <strong>of</strong> pain killing drugs in rheumatic disease<br />
Joan-Ramon Joan-Ramon Laporte Laporte (Spain)<br />
Big Pharma <strong>and</strong> the single way <strong>of</strong> thinking: MSD v Bulletin Groc on r<strong>of</strong>ecoxib<br />
Thierry Thierry Schaeverbeke Schaeverbeke (France)<br />
Disease Modifying Drugs<br />
Gerd Gerd Geisslinger Geisslinger (Germany)<br />
COX-dependent <strong>and</strong> COX-independent effects <strong>of</strong> Coxibs<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Moore Moore N., N., Blin Blin PP<br />
P., P ., F FFourrier<br />
FF<br />
ourrier ourrier A AA.,<br />
A ., Depont Depont F FF.,<br />
F ., Droz-P Droz-Perroteau Droz-P erroteau C., C., Merliere Merliere Y YY.,<br />
Y Y.,<br />
.,<br />
Benichou Benichou Benichou J., J., Moride Moride Y YY.,<br />
Y ., Begaud Begaud Begaud B<br />
B<br />
A description <strong>of</strong> cox-2 inhibitors <strong>and</strong> non-selective nsaid users in france, the cadeus study<br />
Erdogan Erdogan F FF.,<br />
F ., Gokay Gokay S., S., Gulmez Gulmez SE., SE., Ergun Ergun H., H., Bolay Bolay B., B., T TTulunay<br />
TT<br />
ulunay C. C.<br />
C.<br />
Is topically applied nimesulide effective in gonarthrosis?<br />
Jovanovic Jovanovic Jovanovic L., L., L., Prostran Prostran Prostran M., M., M., VV<br />
Vuckovic VV<br />
uckovic S., S., Stojanovic Stojanovic R., R., T TTodorovic<br />
T Todorovic<br />
odorovic Z., Z., Nesic Nesic Z.<br />
Z.<br />
Treatment models <strong>of</strong> chronic musculo-skeletal pain in the frail aged in Belgrade<br />
9.00 9.00 9.00 – – 11:15 11:15 11:15 PHARMACOECONOMICS<br />
PHARMACOECONOMICS<br />
Symposium Symposium run run in in <strong>association</strong> <strong>association</strong> <strong>association</strong> with with ISPOR ISPOR<br />
ISPOR<br />
Chairmen Chairmen Marcin Marcin Czech Czech (Pol<strong>and</strong>)<br />
Tom om om W WWalley<br />
W alley (UK)<br />
Speakers Speakers Speakers Marcin Marcin Czech Czech Czech (Pol<strong>and</strong>)<br />
Pharmacoeconomics – Polish Perspective<br />
Lieven Lieven Lieven Annemans Annemans (Belgium)<br />
Pharmacoeconomics – International Perspective<br />
Lilli Lilli Grell Grell (Germany)<br />
Role <strong>of</strong> pharmacoeconomics in drug evaluation<br />
Jacek Jacek Sp³awinski Sp³awinski (Pol<strong>and</strong>)<br />
Reimbursement at a national level: the role <strong>of</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
Dyfrig Dyfrig Hughes Hughes (UK)<br />
Pharmacokinetics, patient compliance <strong>and</strong> pharmacoeconomics<br />
Free<br />
Free<br />
communi communi-<br />
communi<br />
cations cations Wawruch awruch M., M., Bozekova Bozekova Bozekova L., L., Krcmery Krcmery S., S., K KKozlikova<br />
K Kozlikova<br />
ozlikova K., K., K., F FFoltan<br />
F oltan V VV.,<br />
V ., Lassanova Lassanova Lassanova M., M., Kriska Kriska M.<br />
M.<br />
The pharmacoeconomic advantages <strong>of</strong> switch from intravenous to oral administration <strong>of</strong> antibiotics<br />
Vitezic Vitezic D., D., D., Buble Buble TT<br />
T. T<br />
Cardiovascular drugs: financial consumption increase in croatia<br />
Webb ebb D, D, Bennie Bennie M, M, M, Timoney Timoney A AA.,<br />
A ., Mciver Mciver L., L., P PPaterson<br />
P aterson K.<br />
K.<br />
The Scottish medicines consortium (smc): the feasibility <strong>of</strong> early assessment <strong>of</strong> cost-effectiveness <strong>of</strong><br />
new drugs<br />
– – –
9.00 9.00 – – 11:15 11:15 PHARMACOVIGILANCE<br />
PHARMACOVIGILANCE<br />
Symposium Symposium Symposium Symposium Symposium run run run run run in in in in in <strong>association</strong> <strong>association</strong> <strong>association</strong> <strong>association</strong> <strong>association</strong> with with with with with ISOP ISOP ISOP ISOP ISOP<br />
Chairmen Chairmen Chairmen Nicholas Nicholas Moore Moore (France)<br />
Giampaolo Giampaolo VV<br />
Velo VV<br />
elo (Italy)<br />
Local<br />
Local<br />
coordinator coordinator Przemys³aw Przemys³aw Miko³ajczak Miko³ajczak (Pol<strong>and</strong>)<br />
Speakers Speakers Nicholas Nicholas Moore, Moore, Giampaolo Giampaolo Giampaolo V VVelo<br />
V elo<br />
Introductory remarks<br />
Petra etra Thuermann<br />
Thuermann Thuermann (Germany)<br />
The role <strong>of</strong> regional Pharmacovigilance Centers<br />
Jasper Jasper Hallas Hallas (Denmark)<br />
Improving prescribing by use <strong>of</strong> large prescription data bases<br />
Bruno Bruno Stricker Stricker (Netherl<strong>and</strong>)<br />
The regulator's travel between Scylla <strong>and</strong> Charybdis<br />
János János Borvendég Borvendég (Hungary)<br />
Premarketing <strong>and</strong> Postmarketing pharmacovigilance; the different reporting attitude<br />
<strong>of</strong> the same medical doctors<br />
Free<br />
Free<br />
communicommuni<br />
cations cations cations Polimeni olimeni G., G., Salvo Salvo F FF.,<br />
F ., Morreale Morreale I., I., Cutroneo Cutroneo PM., PM., Caputi Caputi AP AP AP. AP<br />
Adverse reactions induced by NSAIDS <strong>and</strong> antibiotics. Analysis <strong>of</strong> spontaneous reports from<br />
the sicilian regional database<br />
Verge erge C., C., Lucena Lucena MI., MI., MI., PP<br />
Pachkoria P achkoria K., K., Andrade Andrade RJ., RJ., F FFernández<br />
F ernández MC., MC., Durán Durán JA JA., JA ., Costa Costa J.,<br />
J.,<br />
Vaqué aqué aqué A AA.,<br />
A ., Soler Soler A AA.,<br />
A A.,<br />
., Borrás Borrás Borrás A AA.<br />
A<br />
Toxic <strong>and</strong> drug-induced liver injury: an análisis <strong>of</strong> 461 incidences submitted to a registry<br />
over a 10-year period<br />
Diemont Diemont Diemont W WW.,<br />
W ., VV<br />
Van VV<br />
an Puijenbroek Puijenbroek Puijenbroek E., E., Bouwes Bouwes Bavinck Bavinck JN. JN.<br />
JN.<br />
Concept testing: signal generation <strong>and</strong> confirmation <strong>of</strong> severe cutaneous adrs<br />
Huupponen Huupponen R., R., Helin-Salmivaara Helin-Salmivaara AA<br />
A., AA<br />
., Virtanen Virtanen A AA.,<br />
A ., Lammela Lammela J., J., Klaukka Klaukka T TT.<br />
TT<br />
Co-prescribing <strong>of</strong> drugs with potential gastrointestinal toxicity among continuous users <strong>of</strong> NSAIDS<br />
11:15 11:15 – – 11:30 11:30 COFFEE COFFEE BREAK<br />
BREAK<br />
PLENARY PLENARY LECTURE<br />
LECTURE<br />
11:30 11:30 – – 12:15 12:15 Silvio Silvio Garratini<br />
Garratini<br />
Orphan Orphan Orphan Orphan Orphan drugs: drugs: drugs: drugs: drugs: only only only only only <strong>for</strong> <strong>for</strong> <strong>for</strong> <strong>for</strong> <strong>for</strong> rare rare rare rare rare diseases? diseases? diseases? diseases? diseases?<br />
12:15 12:15 – – 12:45 12:45 LUNCH<br />
LUNCH<br />
12:45 12:45 – – 15:00 15:00 POSTER POSTER SESSION<br />
SESSION<br />
POSTER POSTER SESSION SESSION SESSION 13<br />
13<br />
Pharmacovigilance<br />
Pharmacovigilance<br />
POSTER POSTER SESSION SESSION SESSION 14 14<br />
14<br />
Pharmacoeconomics<br />
Pharmacoeconomics<br />
Pharmacoeconomics<br />
POSTER POSTER SESSION SESSION SESSION 15<br />
15<br />
Pharmacoeconomics<br />
Pharmacoeconomics<br />
– – –
15:00 15:00 – – 17:15 17:15 THE THE WISE WISE USE USE OF OF DRUGS DRUGS<br />
DRUGS<br />
Chairmen Chairmen Andrzej Andrzej Danysz Danysz (Pol<strong>and</strong>)<br />
Lars Lars Gustafsson Gustafsson (Sweden)<br />
Speakers Speakers Speakers Michael Michael Rawlins Rawlins (UK)<br />
New drug innovations <strong>and</strong> treatment<br />
Igor Igor F FFrancetic<br />
F rancetic (Croatia)<br />
Drug <strong>and</strong> Therapeutic Committees (DTCs ) in Croatia<br />
Lars Lars Gustafsson Gustafsson (Sweden)<br />
The Stockholm DTC model<br />
Free Free<br />
Free<br />
communicommuni<br />
cations cations Awad Awad A AA.,<br />
A ., Eltayeb Eltayeb IBE. IBE. , , Baraka Baraka OZB.<br />
OZB.<br />
Changing antibiotics prescribing practices in health centres in Sudan<br />
Tirkkonen Tirkkonen T TT.,<br />
T ., Virtanen Virtanen Virtanen A AA.,<br />
A ., Laine Laine K.<br />
K.<br />
Clinical consequences <strong>of</strong> drug interactions with lovastatin <strong>and</strong> simvastatin<br />
Eiermann Eiermann B., B., Laine Laine K., K., Böttiger Böttiger Böttiger Y YY.,<br />
Y ., Gustafsson Gustafsson LL. LL. , , Molin Molin B. B.<br />
B.<br />
From bench- to bedside - developing a knowledge database about drug interactions to be used in<br />
computerized prescribing tools at point-<strong>of</strong>-care in Sweden <strong>and</strong> Finl<strong>and</strong><br />
15:00 15:00 – – 17:15 17:15 PHARMACOGENOMICS<br />
PHARMACOGENOMICS<br />
Chairmen Chairmen Ingolf Ingolf Cascorbi Cascorbi Cascorbi (Germany)<br />
Anders Anders Rane Rane Rane (Sweden)<br />
Local<br />
Local<br />
coordinator coordinator Przemys³aw Przemys³aw Niewiñski<br />
Niewiñski<br />
Speakers Speakers Magnus Magnus Ingelman-Sundberg Ingelman-Sundberg (Sweden)<br />
Novel aspects <strong>of</strong> pharmacogenetics <strong>of</strong> cytochrome P450s<br />
Heyo Heyo K. K. Kroemer Kroemer Kroemer (Germany)<br />
Pharmacogenomics <strong>of</strong> drug transporters<br />
Kim Kim Kim Brosen Brosen (Denmark)<br />
Pharmacogenomics <strong>of</strong> antidepressant therapy<br />
Laurent Laurent Bequemont<br />
Bequemont Bequemont (France)<br />
Translation <strong>of</strong> pharmacogenetics into <strong>clinical</strong> practice<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Ehret Ehret G., G., Chabert Chabert J., J., Daali Daali Y YY.,<br />
Y ., W WWolff<br />
WW<br />
olff A AA.,<br />
A ., Goual Goual F FF.,<br />
F ., F FFritschy<br />
F ritschy D., D., Rossier Rossier M., M., Piguet Piguet V VV.,<br />
VV<br />
.,<br />
Dayer Dayer P PP.,<br />
P ., Desmeules Desmeules J.<br />
J.<br />
Preemptive analgesia induced by the nmda receptor antagonist dextromethorphan : a r<strong>and</strong>omized<br />
controlled study evaluating the impact <strong>of</strong> cyp2d6 phenotype on the post-operative analgesic requirement<br />
Oswald Oswald S., S., Haenisch Haenisch S., S., Remmler Remmler C., C., Giessmann Giessmann T TT.,<br />
T T.,<br />
., Dazert Dazert E., E., W WWarzock<br />
W arzock R., R., Cascorbi Cascorbi I., I.,<br />
I.,<br />
Kroemer Kroemer HK., HK., HK., Siegmund Siegmund WW<br />
W. WW<br />
Disposition <strong>of</strong> the cholesterol uptake inhibitor ezetimibe in man is influenced by the rifampicin inducible<br />
intestinal expression <strong>of</strong> p-glycoprotein, mrp2 <strong>and</strong> ugt1a1<br />
Rane Rane Rane A AA.<br />
A A.<br />
. , , Jakobsson Jakobsson J., J., Inotsume Inotsume Inotsume N., N., Garle Garle M., M., M., Lorentzon Lorentzon Lorentzon M., M., M., Ohlsson Ohlsson C., C., Roh Roh HK., HK., Carlstrom Carlstrom K., K.,<br />
K.,<br />
Ekstrom Ekstrom L.<br />
L.<br />
Differences in testosterone excretion in orientals <strong>and</strong> caucasians explained by a udp-glucuronosyl<br />
transferase 2b17 polymorphism<br />
20.00-24.00 20.00-24.00 GALA GALA DINNER<br />
DINNER<br />
Wednesday Wednesday June June 29, 29, 2005<br />
2005<br />
– – –
9.00 9.00 – – 11:15 11:15 THERAPEUTIC THERAPEUTIC RESEARCH RESEARCH IN IN HIV HIV & & OTHER OTHER VIRAL VIRAL DISEASES<br />
DISEASES<br />
Chairmen Chairmen Detlev Detlev Kruger Kruger (Germany)<br />
Wojciech ojciech S³u¿ewski S³u¿ewski (Pol<strong>and</strong> )<br />
Speakers Speakers Detlev Detlev Kruger Kruger (Germany)<br />
Antiviral therapy: <strong>clinical</strong> needs <strong>and</strong> recent practical development<br />
Helga Helga Ruebsamen-<br />
Ruebsamen-Waigmann<br />
Ruebsamen- aigmann (Germany)<br />
HIV <strong>and</strong>/or other viral diseases on research<br />
Thierry Thierry Buclin Buclin (Switzerl<strong>and</strong>)<br />
Therapeutic Drug Monitoring <strong>of</strong> anti-retroviral agents: necessity or luxury?<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Nesic Nesic Z., Z., Delic Delic D., D., Prostran Prostran M., M., Stojanovic Stojanovic R., R., T TTodorovic<br />
T odorovic Z., Z., V VVuckovic<br />
V Vuckovic<br />
uckovic S. S.<br />
S.<br />
The role <strong>of</strong> age, sex, source <strong>of</strong> infection <strong>and</strong> duration <strong>of</strong> chronic hepatitis c infection on outcome <strong>of</strong><br />
the treatment<br />
Szymanski Szymanski J., J., Haffner Haffner S., S., T TTenter<br />
TT<br />
enter U., U., Sonnenburg Sonnenburg C., C., Thuermann Thuermann P PP.<br />
PP<br />
Safety <strong>and</strong> pharmacokinetic properties <strong>of</strong> the new human hepatitis b immunoglobulin bt088<br />
after subcutaneous <strong>and</strong> intramuscular application in healthy volunteers<br />
9:00 9:00 – – 11:15 11:15 EDUCATION EDUCATION ISSUES ISSUES ISSUES IN IN CPT CPT<br />
CPT<br />
Symposium Symposium run run in in in <strong>association</strong> <strong>association</strong> with with ENOTT<br />
ENOTT<br />
Chairmen Chairmen Tadeusz adeusz Chruœciel Chruœciel (Pol<strong>and</strong>)<br />
Theo Theo de de Vries Vries Vries (Netherl<strong>and</strong>s)<br />
Speakers Speakers Speakers Albert Albert Scherpbier Scherpbier (Netherl<strong>and</strong>s)<br />
The changing role <strong>of</strong> the teacher in modern medical education<br />
S<strong>and</strong>or S<strong>and</strong>or KK<br />
Kerpel-F KK<br />
erpel-F erpel-Fronius<br />
erpel-F ronius (Hungary)<br />
CP Education: from transferring knowledge to learning competencies<br />
Ozden Ozden P PPalaoglu<br />
P alaoglu (Turkey)<br />
How to write [CP] learning objectives<br />
Simon Simon Maxwell Maxwell ( (UK) (<br />
How to teach evidenced-based <strong>clinical</strong> <strong>pharmacology</strong> in medical undergraduate<br />
<strong>and</strong> postgraduate education<br />
Jean Jean Marie Marie Marie Halimi Halimi (France)<br />
Therapeutic Learning Aids<br />
Free<br />
Free<br />
communicommunicommuni<br />
cations cations Krulichova Krulichova I., I., Martinkova Martinkova J., J., J., Chladek Chladek J.<br />
J.<br />
Computer-assisted educative program based on case studies<br />
Franson ranson K., K., Dubois Dubois E., E., De De De Kam Kam M. M. , , Cohen Cohen A AA.<br />
A<br />
Assessing various parameters <strong>of</strong> medical student learning <strong>of</strong> <strong>clinical</strong> <strong>pharmacology</strong><br />
De De P PPaepe<br />
P aepe PP<br />
P., P ., Christiaens Christiaens T TT.,<br />
TT<br />
., P PPetrovic<br />
P etrovic M., M., Struys Struys M., M., V VV<strong>and</strong>er<br />
V <strong>and</strong>er S. S. R.,<br />
R.,<br />
De De De Vries Vries Vries TT<br />
T., TT<br />
., ., VV<br />
Van VV<br />
an an Bortel Bortel Bortel L. L.<br />
L.<br />
Role play sessions in pharmacotherapeutic counselling: evaluation by students<br />
Verbraak erbraak RPH., RPH., RPH., Vries Vries De De T TT.,<br />
T ., Hugtenburg Hugtenburg Hugtenburg J., J., Antonini Antonini N., N., Richir Richir Richir Mc, Mc, Tichelaar Tichelaar J.<br />
J.<br />
Evaluation <strong>of</strong> therapeutic osce <strong>of</strong> pre-<strong>clinical</strong> medical students in the <strong>for</strong>m consulting hours at the<br />
out-patient clinic.<br />
– – –
9:00 9:00 – – 11:15 11:15 DRUG DRUG DELIVERY DELIVERY<br />
DELIVERY<br />
Symposium Symposium Symposium Symposium Symposium run run run run run in in in in in <strong>association</strong> <strong>association</strong> <strong>association</strong> <strong>association</strong> <strong>association</strong> with with with with with EUFEPS EUFEPS EUFEPS EUFEPS EUFEPS<br />
Chairmen Chairmen Kim Kim Dalh<strong>of</strong>f Dalh<strong>of</strong>f (Denmark)<br />
Claus-Michael Claus-Michael Lehr Lehr (Germany)<br />
Speakers Speakers Speakers Claus Claus Michael Michael Lehr Lehr Lehr (Germany)<br />
The use <strong>of</strong> nanotechnology in drug delivery<br />
Manel Manel Barbanoj Barbanoj (Spain)<br />
Clinical perspectives <strong>of</strong> PK-PD studies in drug delivery<br />
Roman Roman Lesyk<br />
Lesyk<br />
4-azolidones <strong>and</strong> related heterocycles. structure , anticancer activity, relationship <strong>and</strong> lead optimization<br />
Gerd Gerd Storm Storm (Netherl<strong>and</strong>s)<br />
Gene delivery with biodegradable Polymers<br />
Free<br />
Free<br />
communicommuni<br />
cations cations Laine Laine K., K., Molsa Molsa M., M., M., Heikkinen Heikkinen T TT.,<br />
T ., Hakkola Hakkola J., J., Hakala Hakala Hakala K., K., W WWallerman<br />
W allerman O OO.,<br />
O ., WW<br />
Wadelius WW<br />
adelius M. M. , , W WWadelius<br />
W adelius L.<br />
L.<br />
Functional role <strong>of</strong> p-glycoprotein in the human blood-placenta barrier<br />
Zara Zara GP GP., GP ., Cavalli Cavalli R., R., Canaparo Canaparo R., R., Serpe Serpe L., L., Muntoni Muntoni E., E., Gasco Gasco MR., MR., MR., E<strong>and</strong>i E<strong>and</strong>i M.<br />
M.<br />
Ophthalmic delivery <strong>of</strong> dexamethasone <strong>and</strong> tobramycin incorporated in solid lipid nanoparticles<br />
11:15 11:15 – – 11:30 11:30 COFFEE COFFEE BREAK<br />
BREAK<br />
PLENARY PLENARY PLENARY LECTURE<br />
LECTURE<br />
11:30 11:30 – – 12:15 12:15 Jan Jan Schellens<br />
Schellens<br />
Molecular based novel anti cancer therapy<br />
12:15 12:15 – – 12:45 12:45 12:45 CLOSING CLOSING CEREMONY<br />
CEREMONY<br />
– – –
SATELLITE SATELLITE EVENTS<br />
EVENTS<br />
WORKSHOP WORKSHOP – – METHODOLOGY METHODOLOGY OF OF CLINICAL CLINICAL TRIALS TRIALS<br />
TRIALS<br />
FRIDAY FRIDAY – – SATURDAY, SATURDAY, JUNE JUNE 24-25, 24-25, 24-25, 2005<br />
2005<br />
PROGRAMME:<br />
PROGRAMME:<br />
Chair: Chair: Domenico Criscuolo (Italy)<br />
Andrzej Cz³onkowski (Pol<strong>and</strong>)<br />
Przemys³aw M. Mrozikiewicz (Pol<strong>and</strong>)<br />
FRIDAY, FRIDAY, FRIDAY, JUNE JUNE 24, 24, 2005<br />
2005<br />
9.00: Introduction Domenico Domenico Criscuolo Criscuolo (Italy)<br />
9.15: Introduction Andrzej Andrzej Andrzej Cz³onkowski Cz³onkowski (Pol<strong>and</strong>)<br />
9.30: Introduction to methodology <strong>of</strong> Clinical Trials Paola aola Antonin Antonini Antonin (Italy)<br />
10.30: C<strong>of</strong>fee C<strong>of</strong>fee C<strong>of</strong>fee break<br />
break<br />
10.45: Ethics <strong>of</strong> <strong>clinical</strong> investigation <strong>and</strong> placebo use Krystyna Krystyna Orzechowska-Juzwenko Orzechowska-Juzwenko (Pol<strong>and</strong>)<br />
11.25: The drug development process Domenico Domenico Domenico Criscuolo Criscuolo (Italy)<br />
12.25: The development <strong>of</strong> Good Clinical Practice Jane Jane Barrett Barrett (UK)<br />
13.25: Lunch<br />
Lunch<br />
14.30: Conflict <strong>of</strong> interest in science <strong>and</strong> medicine Andrzej Andrzej Górski Górski (Pol<strong>and</strong>)<br />
15.30: The role <strong>of</strong> Quality Assurance in <strong>clinical</strong> trials Rafael Rafael Rak Rak (Germany)<br />
16.15: Role <strong>and</strong> responsibilities <strong>of</strong> Sponsors Gerfried Gerfried Nell Nell (Austria)<br />
17.00: End End <strong>of</strong> <strong>of</strong> day day 1<br />
1<br />
SATURDAY, SATURDAY, JUNE JUNE 25, 25, 2005<br />
2005<br />
9.00: Introduction Andrzej Andrzej Cz³onkowski Cz³onkowski (Pol<strong>and</strong>), Domenico Domenico Criscuolo Criscuolo (Italy)<br />
9.15: Impact <strong>of</strong> globalisation on <strong>clinical</strong> research Marcin Marcin W WWalter<br />
W alter (Pol<strong>and</strong>)<br />
10.00: Social aspects <strong>of</strong> <strong>clinical</strong> research Wojciech ojciech ojciech Mase³bas Mase³bas (Pol<strong>and</strong>)<br />
10.45: Role <strong>and</strong> responsibilities <strong>of</strong> Monitors Juan Juan Lahuerta Lahuerta (Hiszpania)<br />
11.30: C<strong>of</strong>fee C<strong>of</strong>fee break<br />
break<br />
11.45: Investigators <strong>and</strong> in<strong>for</strong>med consent Amnon Amnon Carmi Carmi (Israel)<br />
12.30: The importance <strong>of</strong> Drug Surveillance Veronique eronique Basch Basch (Switzerl<strong>and</strong>)<br />
13.15: Regulatory issues in European countries John John Hladkiwskyj Hladkiwskyj (UK)<br />
14.00: Lunch<br />
Lunch<br />
15.00: How to comply with m<strong>and</strong>atory electronic serious adverse event reporting requirements <strong>for</strong> <strong>clinical</strong> trials conducted in the EU<br />
Wolfram olfram olfram Richter Richter (Germany)<br />
15.30: Clinical trials in Pol<strong>and</strong> – practical approach Janusz Janusz Kamiñski Kamiñski (Pol<strong>and</strong>)<br />
16.00: The insurance <strong>of</strong> <strong>clinical</strong> trials in Pol<strong>and</strong> Marek Marek Marek Kidziñski Kidziñski (Pol<strong>and</strong>)<br />
16.30: End End <strong>of</strong> <strong>of</strong> <strong>of</strong> day day day 2<br />
2<br />
SUNDAY, SUNDAY, SUNDAY, JUNE JUNE 26, 26, 26, 2005, 2005, 12.45 12.45 – – 15.00<br />
15.00<br />
POLISH POLISH CPT CPT CPT MEETING<br />
MEETING<br />
DRUG DRUG DRUG SAFETY SAFETY AS ASSES AS ASSES<br />
SES SESSMENT SES SMENT AND AND RISK RISK MANAGEMENT<br />
MANAGEMENT<br />
Chair: Chair: Andrzej Czarnecki<br />
Stephen Evans<br />
Andrzej Andrzej Czarnecki Czarnecki Principles <strong>of</strong> drug safety surveillance <strong>and</strong> evaluation<br />
Stephen Stephen Evans Evans Data mining <strong>and</strong> signal detection from large databases<br />
Saad Saad Shakir Shakir<br />
Principles <strong>of</strong> causality assessment<br />
Nicholas Nicholas Moore Moore Risk Management throughout the life cycle <strong>of</strong> the drug<br />
MONDAY MONDAY JUNE JUNE 27, 27, 27, 2005, 2005, 12.45 12.45 - - 15.00<br />
15.00<br />
POLISH POLISH CPT CPT MEETING<br />
MEETING<br />
BIOTECHNOL<br />
BIOTECHNOLOGY BIOTECHNOL OGY AND AND CLINICAL CLINICAL PHARMACOL<br />
PHARMACOLOGY<br />
PHARMACOL OGY<br />
Ryszard S³omski<br />
Olfert L<strong>and</strong>t<br />
Przemys³aw M. Mrozikiewicz<br />
TUESDAY, TUESDAY, TUESDAY, JUNE JUNE 28, 28, 28, 2005, 2005, 12.45-15.00<br />
12.45-15.00<br />
POLISH POLISH CPT CPT MEETING<br />
MEETING<br />
ANTIBIOTIC<br />
ANTIBIOTIC<br />
ANTIBIOTICS<br />
ANTIBIOTIC<br />
Speakers Richard Wise<br />
Ana Sabo<br />
Krzyszt<strong>of</strong> Drews<br />
Andrzej Radzikowski<br />
WEDNESDAY WEDNESDAY JUNE JUNE 29, 29, 2005, 2005, 12.45-15.00<br />
12.45-15.00<br />
CLINICAL CLINICAL PHARMACOL<br />
PHARMACOLOGY PHARMACOL OGY IN IN EASTERN EASTERN EUROPE EUROPE - - THE THE ROLES ROLES IN IN TEACHING, TEACHING, RESEARCH RESEARCH AND AND HEAL HEALTH HEAL TH CARE CARE CARE DELIVERY<br />
DELIVERY<br />
Sponsored Sponsored by by IUPHAR<br />
IUPHAR<br />
Chairmen Chairmen Folke Sjöqvist (Sweden)<br />
Milan Grundman (Czech Republic)<br />
States States <strong>of</strong> <strong>of</strong> the the the Art Art Art Bulgaria Emil Gatchev (S<strong>of</strong>ia)<br />
Clinical <strong>pharmacology</strong> in Bulgaria: present status<br />
Serbia Slobodan Jankovic (Kragujevac)<br />
Clinical Pharmacology in Serbia - state <strong>of</strong> the art<br />
Russia Lilia Ziganshina (Kazan)<br />
Clinical Pharmacology in the Republic <strong>of</strong> Tatarstan (Russian Federation)<br />
Estonia Raul Kiivet (Tartu)<br />
Clinical Pharmacology in Estonia<br />
Stumbling blocks hindering the development <strong>of</strong> <strong>clinical</strong> <strong>pharmacology</strong> – experience from Central <strong>and</strong> Western Europe<br />
Czech Republic Milan Milan Grundmann Grundmann (Ostrava )<br />
Spain Nicolas Nicolas Boada Boada (Tenerife)<br />
UK David David David J J J WW<br />
Webb WW<br />
ebb (Edinburgh)<br />
Comments <strong>and</strong> Conclusions Folke olke Sjoqvist Sjoqvist (IUPHAR)<br />
– – –
POSTER POSTER SESSION SESSION 1<br />
1<br />
POSTER POSTER SESSION SESSION 1<br />
1<br />
77. 77. COMPARISON COMPARISON OF OF ACUTE ACUTE POISONING POISONING DATA: DATA: DATA: DIRECT DIRECT SURVEY SURVEY AND AND AND TELEPHONE TELEPHONE REPORTING<br />
REPORTING<br />
OF OF POISONING POISONING EXPOSURES<br />
EXPOSURES<br />
Bilusic Bilusic M., M., FF<br />
Francetic F rancetic I., I., Macolic Macolic Sarinic Sarinic V VV.,<br />
V ., Makar Makar-Ausperger Makar -Ausperger K., K., K., Erdeljic Erdeljic V VV.<br />
V<br />
Division <strong>of</strong> Clinica Pharmacology, Department <strong>of</strong> Medicine, University Hospital Zagreb, Croatia<br />
476. 476. 476. PLACEBO PLACEBO USE USE IN IN RANDOMISED RANDOMISED RANDOMISED CONTROLLED CONTROLLED TRIALS TRIALS OF OF PSYCHIATRIC PSYCHIATRIC DISORDER<br />
DISORDER<br />
Ramirez Ramirez E. E. 1 2 2 2 2 2 2<br />
, , Llanos Llanos Llanos L. L. , , Laosa Laosa O OO.<br />
O , , Ochoa Ochoa D. D. , , Romero Romero IA IA. IA , , F FFrias<br />
F rias J. J. , , AJ. AJ. Carcas Carcas<br />
1 La Paz Hospital/ Autonoma University <strong>of</strong> Madrid, Madrid<br />
2 La Paz Hospital/ Autonoma University <strong>of</strong> Madrid, Clinical Pharmacology, Madrid<br />
79. 79. THE THE PHARMACOKINETICS PHARMACOKINETICS OF OF DILTIAZEM DILTIAZEM AND AND ITS ITS METABOLITES METABOLITES IN IN IN HEALTHY HEALTHY MEN MEN AFTER AFTER SINGLE<br />
SINGLE<br />
AND AND MULTIPLE MULTIPLE DOSE DOSE OF OF PROLONGED-RELEASE PROLONGED-RELEASE PREPARATION PREPARATION WITH WITH ROUGH ROUGH EVALUATION<br />
EVALUATION<br />
EVALUATION<br />
THE THE THE PHARMACOLOGICAL PHARMACOLOGICAL EFFECT<br />
EFFECT<br />
Bogiel Bogiel M. M. 1 1 2 3 1<br />
, , Duda Duda J. J. , , P PPawlowska<br />
P Pawlowska<br />
awlowska M. M. , , Grzesk Grzesk G. G. , , Marzec Marzec A AA.<br />
A<br />
1 Institute <strong>of</strong> Biotechnology <strong>and</strong> Antibiotics, Warszawa, Pol<strong>and</strong><br />
2 Insytytut Biotechnologii i Antybiotyków, Warszawa, Pol<strong>and</strong><br />
3 Medical University, Bydgoszcz, Pol<strong>and</strong><br />
80. 80. 80. PHARMACOKINETICS PHARMACOKINETICS PHARMACOKINETICS OF OF OF INDAPAMIDE INDAPAMIDE INDAPAMIDE AFTER AFTER AFTER SINGLE SINGLE SINGLE AND AND AND MULTIPLE MULTIPLE MULTIPLE DOSE DOSE DOSE OF OF OF SLOW-RELEASE<br />
SLOW-RELEASE<br />
SLOW-RELEASE<br />
PREPARATION PREPARATION WITH WITH EVALUATION EVALUATION OF OF ABSORPTION ABSORPTION CHARACTERISTICS.<br />
CHARACTERISTICS.<br />
CHARACTERISTICS.<br />
Duda Duda J. J. 1 1 1 2<br />
, , , Marzec Marzec Marzec A AA.<br />
A , , , Bogiel Bogiel Bogiel M. M. M. , , Sieradzki Sieradzki Sieradzki E. E.<br />
1 Institute <strong>of</strong> Biotechnology <strong>and</strong> Antibiotics, Warszawa, Pol<strong>and</strong><br />
2 Medical University in Warsaw, Warszawa, Pol<strong>and</strong><br />
81. 81. PUBLIC PUBLIC FUNDING FUNDING FUNDING OF OF DRUGS DRUGS FOR FOR FOR ORPHAN ORPHAN DISEASES.<br />
DISEASES.<br />
Hughes Hughes D. D. 1<br />
1 University <strong>of</strong> Wales, Bangor, Bangor, UK<br />
84. 84. INFLUENCE INFLUENCE OF OF ADHERENCE ADHERENCE TO TO CLINICAL CLINICAL GUIDELINES GUIDELINES IN IN IN EMPIRIC EMPIRIC ANTIBIOTICS ANTIBIOTICS CHOICE CHOICE<br />
CHOICE<br />
ON ON OUTCOMES OUTCOMES OF OF COMMUNITY-ACQUIRED COMMUNITY-ACQUIRED PNEUMONIA PNEUMONIA IN IN HOSPITALIZED HOSPITALIZED BELARUSSIAN BELARUSSIAN PATIENTS.<br />
PATIENTS.<br />
Mily Mily Mily M. M. 1 2 1 3<br />
, , , Golubev Golubev S. S. , , , Sachek Sachek M. M. , , , VV<br />
Voronov VV<br />
oronov oronov G. G.<br />
1 State Medical University, Vitebsk, Ukraine<br />
2 Vitebsk Regional Clinical Hospital, Vitebsk, Ukrain<br />
3 National Center <strong>for</strong> Research in Health Care, Minsk, Ukraine<br />
85. 85. LIGHT LIGHT LIGHT EVOKED EVOKED PUPILLOGRAPHY; PUPILLOGRAPHY; A A SENSITIVE SENSITIVE CLINICAL CLINICAL BIOMARKER BIOMARKER BIOMARKER FOR FOR FOR 5-HT1A 5-HT1A COMPOUNDS<br />
COMPOUNDS<br />
WITH WITH DOPAMINE DOPAMINE AGONISTIC AGONISTIC PROPERTIES<br />
PROPERTIES<br />
Boettcher Boettcher Boettcher MF MF. MF 1 1 1 2<br />
, , Brendel Brendel E. E. , , K KKuhlmann<br />
KK<br />
uhlmann uhlmann J. J. , , W WWensing<br />
W ensing G. G.<br />
1 Bayer HealthCare AG, Institute <strong>of</strong> Clinical Pharmacology, Wuppertal, Germany<br />
2 Institute <strong>of</strong> Clinical Pharmacology, Bayer HealthCare, Wuppertal, Germany<br />
86. 86. SUITABILITY SUITABILITY OF OF THE THE CEDIA CEDIA CYCLOSPORINE CYCLOSPORINE PLUS PLUS ASSAY ASSAY FOR FOR CICLOSPORIN CICLOSPORIN QUANTIFICATION<br />
QUANTIFICATION<br />
IN IN PHARMACOKINETIC PHARMACOKINETIC STUDIES<br />
STUDIES<br />
Bauer Bauer Bauer S., S., Mai Mai I., I., I., Johne Johne A AA.,<br />
A ., Roots Roots Roots I. I.<br />
I.<br />
Charité - Universitaetsmedizin Berlin, Institute <strong>of</strong> Clinical Pharmacology, Berlin, Germany<br />
88. 88. 88. DRUG DRUG TRIALS TRIALS IN IN BELARUS: BELARUS: DEGREE DEGREE OF OF COMPLIANCE COMPLIANCE WITH WITH WITH EVIDENCE-BASED EVIDENCE-BASED MEDICINE MEDICINE PRINCIPLES<br />
PRINCIPLES<br />
PRINCIPLES<br />
Mily Mily M. M. 1 2<br />
, , Golubev Golubev Golubev S. S.<br />
1 State Medical University, Vitebsk, Belarus<br />
2 Vitebsk Regional Clinical Hospital, Vitebsk, Belarus<br />
89. 89. EARLY EARLY POM/POP POM/POP IN IN HEALTHY HEALTHY VOLUNTEERS VOLUNTEERS OR OR PATIENTS? PATIENTS? - - EXAMPLE EXAMPLE OF OF AN AN ANGIOTENSIN-II ANGIOTENSIN-II ANTAGONIST<br />
ANTAGONIST<br />
Wensing ensing G., G., Ochmann Ochmann Ochmann K., K., K., Boettcher Boettcher M., M., Zuehlsdorf Zuehlsdorf M, M, K KKuhlmann<br />
K Kuhlmann<br />
uhlmann J.<br />
J.<br />
Bayer HealthCare AG, Institute <strong>of</strong> Clinical Pharmacology, Wuppertal, Germany<br />
– – –
90. 90. 90. OBJECTIVE OBJECTIVE STRUCTURED STRUCTURED CLINICAL CLINICAL CLINICAL EXAMINATIONS EXAMINATIONS (OSCE'S) (OSCE'S) OF OF OF PHARMACOTHERAPEUTIC<br />
PHARMACOTHERAPEUTIC<br />
COUNSELLING: COUNSELLING: COMPETENCE COMPETENCE ASSESSMENT ASSESSMENT BY BY TEACHERS TEACHERS AND AND STUDENTS<br />
STUDENTS<br />
STUDENTS<br />
De De P PPaepe<br />
P aepe P PP.<br />
P 1 1 1 1 1 2 1<br />
, , Christiaens Christiaens TT<br />
T. T , , , PP<br />
Petrovic P etrovic M. M. , , Struys Struys M. M. , , VV<br />
V<strong>and</strong>er VV<br />
<strong>and</strong>er R. R. , , De De De Vries Vries Vries T TT.<br />
T , , VV<br />
Van VV<br />
an Bortel Bortel L. L.<br />
1 Ghent University, Heymans Institute <strong>of</strong> Pharmacology, Ghent, Belgium<br />
2 VU Medical Centre, Department <strong>of</strong> Medical Pharmacology, Amsterdam, Netherl<strong>and</strong>s<br />
92. 92. SHOULD SHOULD PHARMACOECONOMY PHARMACOECONOMY BE BE A A A PART PART PART OF OF UNDERGRADUATE UNDERGRADUATE EDUCATION EDUCATION AT AT AT MEDICAL MEDICAL MEDICAL SCHOOLS?<br />
SCHOOLS?<br />
Tulunay ulunay C. C. 1 2 1<br />
, , Gulmez Gulmez SE. SE. , , Ergun Ergun Ergun H. H.<br />
1 Medical School <strong>of</strong> Ankara University, Department <strong>of</strong> Pharmacology <strong>and</strong> Clinical Pharmacology, Ankara, Turkey<br />
2 Medical School <strong>of</strong> Ankara University, Ankara, Turkey<br />
93. 93. DEVELOPMENT DEVELOPMENT OF OF AN AN INTERNET INTERNET DATABASE DATABASE FOR FOR AN AN EDUCATIONAL EDUCATIONAL STUDY STUDY ON ON APPROPIRIATE<br />
APPROPIRIATE<br />
APPROPIRIATE<br />
USE USE OF OF MEDICINES<br />
MEDICINES<br />
Jaf Jaf Z., Z., Z., Jaf Jaf T TT.,<br />
T ., Borgsteede Borgsteede S., S., Hugtenburg Hugtenburg J., J., De De Vries Vries T TT.<br />
T<br />
VU university medical center, Amsterdam, Netherl<strong>and</strong>s<br />
94. 94. 94. ELECTRONIC ELECTRONIC SYSTEM SYSTEM FOR FOR REGISTRATION REGISTRATION OF OF MEDICAL MEDICAL STUDENTS STUDENTS FOR FOR TRAINING TRAINING AND AND EXAMINATION<br />
EXAMINATION<br />
Jaf Jaf T TT.,<br />
T ., Jaf Jaf Jaf Z., Z., Hugtenburg Hugtenburg J., J., Richir Richir M., M., De De Vries Vries T TT.<br />
T<br />
VU university medical center, Amsterdam, Netherl<strong>and</strong>s<br />
POSTER POSTER SESSION SESSION 2<br />
2<br />
98. 98. THE THE ROLE ROLE ROLE OF OF OF PHARMACEUTICAL PHARMACEUTICAL CARE CARE CARE FOR FOR FOR OPTIMIZATION OPTIMIZATION PATIENTS' PATIENTS' PATIENTS' TREATMENT<br />
TREATMENT<br />
Petkova etkova V VV.<br />
V<br />
Faculty <strong>of</strong> Pharmacy, Medical University, Social Pharmacy, S<strong>of</strong>ia, Bulgaria<br />
99. 99. ENDOGENUS ENDOGENUS DRUG-LIKE DRUG-LIKE FACTORS FACTORS<br />
FACTORS<br />
Mrozikiewicz Mrozikiewicz A AA.<br />
A 1 2<br />
, , Kie³czewska-Mrozikiewicz Kie³czewska-Mrozikiewicz Kie³czewska-Mrozikiewicz D. D. D.<br />
1 Research Institute <strong>of</strong> Medical Plants, Poznan, Pol<strong>and</strong><br />
2 Department <strong>of</strong> Pediatrics Endocrinology <strong>and</strong> Diabetology, University <strong>of</strong> Medical Sciences, Poznañ, Pol<strong>and</strong><br />
100. 100. CLINICAL CLINICAL CLINICAL PHARMACOLOGY PHARMACOLOGY PHARMACOLOGY IN IN IN HEALTH HEALTH CARE<br />
CARE<br />
Jankovic Jankovic S.<br />
S.<br />
Clinical Hospital Center, Kragujevac, Yugoslavia<br />
101. 101. PAEDIATRIC PAEDIATRIC PHARMACOKINETIC PHARMACOKINETIC MODELLING MODELLING USING USING ADAPT(R)<br />
ADAPT(R)<br />
Mifsud Mifsud J., J., J., Shabbi Shabbi H., H., Soler Soler D. D.<br />
D.<br />
University <strong>of</strong> Malta, Msida, Malta<br />
102. 102. EMPIRICAL EMPIRICAL ANALYSIS ANALYSIS OF OF THE THE RELATIONSHIP RELATIONSHIP BETWEEN BETWEEN DOSE DOSE AND AND AND DURATION DURATION OF OF DRUG DRUG ACTION ACTION<br />
ACTION<br />
Hughes Hughes Hughes D. D. 1 2 2<br />
, , Purser Purser L. L. , , W WWalley<br />
W alley T TT.<br />
T<br />
1 University <strong>of</strong> Wales, Bangor, Bangor, UK<br />
2 University <strong>of</strong> Liverpool, Department <strong>of</strong> Pharmacology & Therapeutics, Liverpool, UK<br />
103. 103. CLINICAL CLINICAL PHARMACOLOGICAL PHARMACOLOGICAL PHARMACOLOGICAL COUNSELING COUNSELING AT AT BISPEBJERG BISPEBJERG HOSPITAL, HOSPITAL, DENMARK, DENMARK, 2004<br />
2004<br />
Reuther Reuther L.<br />
L.<br />
Bispebjerg Hospital, Dept. <strong>of</strong> Clinical Pharmacology, Copenhagen, Denmark<br />
104. 104. BLOOD BLOOD FLOW FLOW MEASUREMENT MEASUREMENT MEASUREMENT IN IN IN ENDOMETRIAL ENDOMETRIAL VESSELS VESSELS AND AND UTERINE UTERINE ARTERIES ARTERIES IN IN IN PATIENTS<br />
PATIENTS<br />
TAKING TAKING HORMONAL HORMONAL HORMONAL REPLACEMENT REPLACEMENT THERAPY. THERAPY.<br />
THERAPY.<br />
Moszynski Moszynski R. R. 1 1 2 1 1<br />
, , Szpurek Szpurek Szpurek D. D. , , Mrozikiewicz Mrozikiewicz Mrozikiewicz PM. PM. , , Golon Golon - - Englert Englert M. M. , , Sajdak Sajdak S. S.<br />
1 Poznan University <strong>of</strong> Medical Sciences, Division <strong>of</strong> Gynecological Surgery, Department <strong>of</strong> Gynecology<br />
<strong>and</strong> Obstetrics, Poznan, Pol<strong>and</strong><br />
2 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
105. 105. INFLUENCE INFLUENCE OF OF OF MKCA MKCA ON ON AMPICILLIN AMPICILLIN ABSORPTION ABSORPTION AFTER AFTER ORAL ORAL INTAKE INTAKE OF OF OF AMPICILLIN<br />
AMPICILLIN<br />
Dudvarski Dudvarski D., D., Mikov Mikov M., M., V VVukmirovic<br />
V ukmirovic S., S., Sabo Sabo A AA.<br />
A<br />
Medical Faculty <strong>of</strong> Novi Sad, Novi Sad, Yugoslavia<br />
– – –
106. 106. 106. EFFECTS EFFECTS OF OF PROGESTERONE PROGESTERONE ON ON CA3 CA3 REGION REGION OF OF OF HIPPOCAMPUS HIPPOCAMPUS IN IN MALE MALE RATS<br />
RATS<br />
Kohbanani ohbanani ohbanani MS.<br />
MS.<br />
Rafsanjan University <strong>of</strong> Medical Sciences, Rafsanjan, Iran<br />
107. 107. HORMONAL HORMONAL REPLACEMENT REPLACEMENT THERAPY THERAPY IMPACT IMPACT ON ON DIAGNOSTIC DIAGNOSTIC VALUE VALUE OF OF DOPPLER DOPPLER INDEX<br />
INDEX<br />
IN IN IN POSTMENOPAUSAL POSTMENOPAUSAL POSTMENOPAUSAL WOMEN WOMEN WITH WITH OVARIAN OVARIAN MASSES<br />
MASSES<br />
Szpurek Szpurek D. D. 1 1 2 1 1<br />
, , Moszynski Moszynski R. R. , , Mrozikiewicz Mrozikiewicz PM. PM. , , Golon Golon - - Englert Englert M. M. , , Sajdak Sajdak S. S.<br />
1 Poznan University <strong>of</strong> Medical Sciences, Division <strong>of</strong> Gynecological Surgery, Department <strong>of</strong> Gynecology<br />
<strong>and</strong> Obstetrics, Poznan, Pol<strong>and</strong><br />
2 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
108. 108. MONITORING MONITORING OF OF MYCOPHENOLIC MYCOPHENOLIC ACID ACID IN IN ADULT ADULT RENAL RENAL TRANSPLANT TRANSPLANT RECIPIENTS:<br />
RECIPIENTS:<br />
RECIPIENTS:<br />
THE THE VALUE VALUE OF OF ROC ROC CURVE CURVE ANALYSIS ANALYSIS IN IN DETERMINATION DETERMINATION PHARMACOKINETIC PHARMACOKINETIC VARIABLE<br />
VARIABLE<br />
DISCRIMINATING DISCRIMINATING PATIENTS PATIENTS PATIENTS WITH WITH AN AN ACUTE ACUTE REJECTION<br />
REJECTION<br />
Pawiñski awiñski T TT.,<br />
T T.,<br />
., Durlik Durlik M., M., Szlaska Szlaska I., I., Urbanowicz Urbanowicz A AA.,<br />
A ., Majchrzak Majchrzak J., J., Gralak Gralak B.<br />
B.<br />
Medical Academy, Department <strong>of</strong> Drug Chemistry, Warszawa, Pol<strong>and</strong><br />
109. 109. OVERESTIMATION OVERESTIMATION OF OF VANCOMYCIN VANCOMYCIN SERUM SERUM LEVELS LEVELS BY BY FLUORESCENCE FLUORESCENCE POLARIZATION POLARIZATION POLARIZATION IMMUNO-<br />
IMMUNO-<br />
ASSAY ASSAY (FPIA) (FPIA) METHOD METHOD AS AS COMPARED COMPARED TO TO HIGH HIGH PERFORMANCE PERFORMANCE LIQUID LIQUID LIQUID CHROMATOGRAPHY<br />
CHROMATOGRAPHY<br />
(HPLC): (HPLC): A A CHALLENGE CHALLENGE FOR FOR INTERPRETATION INTERPRETATION DURING DURING THERAPEUTIC THERAPEUTIC THERAPEUTIC DRUG DRUG MONITORING MONITORING .<br />
.<br />
Tesfaye esfaye H., H., Stambergova Stambergova A AA.,<br />
A ., Ulbrichova Ulbrichova Z. Z.<br />
Z.<br />
Department <strong>of</strong> Clinical Pharmacology, Diabetes Centre, Institute <strong>for</strong> Clinical <strong>and</strong> Experimental Medicine, Prague , Czech Republic<br />
110. 110. POPULATION POPULATION PHARMACOKINETICS PHARMACOKINETICS PHARMACOKINETICS OF OF HIGH-DOSE HIGH-DOSE MTX MTX MTX IN IN IN CHILDREN CHILDREN WITH WITH ACUTE ACUTE<br />
ACUTE<br />
LYMPHOBLASTIC LYMPHOBLASTIC LYMPHOBLASTIC LEUKEMIA LEUKEMIA (ALL)<br />
(ALL)<br />
Martinkova Martinkova J., J., J., Chladek Chladek Chladek J., J., Krulichova Krulichova I. I.<br />
I.<br />
Charles University in Prague, Medical Faculty in Hradec Kralove, Department <strong>of</strong> <strong>pharmacology</strong>, Hradec Kralove,Czech Republic<br />
111. 111. TISSUE TISSUE DISTRIBUTION DISTRIBUTION OF OF AMPHOTERICIN AMPHOTERICIN B B LIPID-FORMUALTIONS LIPID-FORMUALTIONS IN IN AUTOPSY AUTOPSY MATERIAL<br />
MATERIAL<br />
Vogelsinger ogelsinger H., H., Djanani Djanani A AA.,<br />
A A.,<br />
., Bellmann Bellmann Bellmann - - W WWeiler<br />
W eiler R., R., R., W WWiedermann<br />
W iedermann ChJ., ChJ., ChJ., Bellmann Bellmann R.<br />
R.<br />
Innsbruck Medical School, Dpt. Internal Medicine, Innsbruck, Austria<br />
112. 112. 112. TOPIRAMATE TOPIRAMATE GLC GLC GLC ANALYSIS ANALYSIS BY BY ON ON COLUMN COLUMN COLUMN DERIVATISATION DERIVATISATION AND AND AND CORRELATION CORRELATION WITH WITH FPIA FPIA METHOD<br />
METHOD<br />
Brozmanova Brozmanova H. H. 1 2 3 3<br />
, , Urinovska Urinovska Urinovska R. R. , , , K KKomzakova<br />
K omzakova I. I. , , , Grundmann Grundmann M. M.<br />
1 University Hospital <strong>and</strong> Medico-Social Faculty, Univ. <strong>of</strong> Ostrava, Ostrava, Czech Republic<br />
2 University <strong>of</strong> Pardubice, Biol. Biochem. Sciences, Pardubice, Czech Republic<br />
3 University Hospital <strong>and</strong> Medico-Social Faculty, Univ. <strong>of</strong> Ostrava, Clinical Pharmacology, Ostrava, Czech Republic<br />
113. 113. POTENTIAL POTENTIAL NEW NEW INDICATIONS INDICATIONS OF OF AMIFOSTINE<br />
AMIFOSTINE<br />
Dobric Dobric S. S. 1 1 1 2 2<br />
, , Simic Simic VD. VD. , , Bokonjic Bokonjic D. D. , , Cupic Cupic V VV.<br />
V , , P PPejcic<br />
P ejcic Z. Z.<br />
1 Military Medical Academy, National Poison Control Centre, Belgrade, Yugoslavia<br />
2 University <strong>of</strong> Belgrade, Faculty <strong>of</strong> Veterinary Medicine, Belgrade, Yugoslavia<br />
114. 114. RESULTS RESULTS OF OF A A CLINICAL CLINICAL STUDY STUDY STUDY OF OF PROPROTEN PROPROTEN EFFICACY EFFICACY AND AND SAFETY SAFETY IN IN ANXIETY ANXIETY DISORDERS<br />
DISORDERS<br />
DISORDERS<br />
Digina Digina JL., JL., Martyushev Martyushev - - P PPoklad<br />
P oklad A AAV.,<br />
A ., Epstein Epstein OI., OI., Sergeeva Sergeeva SA SA. SA<br />
Materia Medica Holding Reasearch <strong>and</strong> Production Company, Moscow, Russia<br />
115. 115. ROFECOXIB ROFECOXIB GREATLY GREATLY GREATLY INCREASES INCREASES PLASMA PLASMA CONCENTRATIONS CONCENTRATIONS AND AND ADVERSE ADVERSE EFFECTS EFFECTS<br />
EFFECTS<br />
OF OF TIZANIDINE TIZANIDINE BY BY INHIBITING INHIBITING STRONGLY STRONGLY STRONGLY ITS ITS CYP1A2 CYP1A2 MEDIATED MEDIATED METABOLISM<br />
METABOLISM<br />
Karjalainen Karjalainen MJ., MJ., Backmann Backmann JT JT., JT ., Gran<strong>for</strong>s Gran<strong>for</strong>s MT MT MT., MT ., Neuvonen Neuvonen Neuvonen M., M., Laitila Laitila J., J., Neuvonen Neuvonen Neuvonen PJ.<br />
PJ.<br />
University <strong>of</strong> Helsinki, Clinical Pharmacology, Helsinki, Finl<strong>and</strong><br />
116. 116. EFFICACY EFFICACY OF OF MONOTHERAPY MONOTHERAPY MONOTHERAPY WITH WITH ANTIEPILEPTIC ANTIEPILEPTIC DRUGS DRUGS SODIUM SODIUM VALPROATE VALPROATE VALPROATE AND<br />
AND<br />
OXCARBAZEPINE OXCARBAZEPINE IN IN CHILDREN CHILDREN WITH WITH BRONCHIAL BRONCHIAL ASTHMA: ASTHMA: IS IS ASTHMA ASTHMA ASTHMA A A NEUROLOGICAL<br />
NEUROLOGICAL<br />
PAROXYSMAL PAROXYSMAL DISEASE?<br />
DISEASE?<br />
Lomia Lomia M. M. M. 1 2 3<br />
, , Chapichadze Chapichadze Z. Z. Z. , , Pruidze Pruidze Pruidze M. M.<br />
1 "Rea" Rehabilitation Centre, Tbilisi, Georgia<br />
2 Pharmacological Committee <strong>of</strong> Ministry <strong>of</strong> Health, Clinical investigations, Tbilisi, Georgia<br />
3 Chinese Medical Centre, Tbilisi, Georgia<br />
– – –
117. 117. 117. PHARMACODYNAMIC-PHARMACOKINETIC PHARMACODYNAMIC-PHARMACOKINETIC CORRELATIONS CORRELATIONS IN IN PATIENTS PATIENTS PATIENTS WITH WITH SYSTEMIC<br />
SYSTEMIC<br />
INFLAMMATORY INFLAMMATORY RESPONSE RESPONSE RESPONSE SYNDROME, SYNDROME, TREATED TREATED WITH WITH PENTOXIFYLLINE PENTOXIFYLLINE PENTOXIFYLLINE INFUSION INFUSION<br />
INFUSION<br />
Padrini adrini R. R. 1 2 2 2<br />
, , Barbieri Barbieri S S , , , F FFeltracco<br />
F eltracco P PP.<br />
P , , Meroni Meroni M. M.<br />
1 University <strong>of</strong> Padova, Padova, Italy<br />
2 Azienda Ospedaliera di Padova, Terapia Intensiva, Padova, Italy<br />
118. 118. CURRENT CURRENT CURRENT STATUS STATUS OF OF CLINICAL CLINICAL PHARMACOLOGY PHARMACOLOGY IN IN SERBIA SERBIA AND AND MONTENEGRO:<br />
MONTENEGRO:<br />
RESULTS RESULTS RESULTS OF OF QUESTIONNAIRE<br />
QUESTIONNAIRE<br />
QUESTIONNAIRE<br />
Dragojevic-Simic Dragojevic-Simic V VV.<br />
V 1 1 2 3 1<br />
, , Stojiljkovic Stojiljkovic M. M. M. , , Stojanovic Stojanovic Stojanovic R. R. , , Raskovic Raskovic A AA.<br />
A , , Bokonjic Bokonjic D. D.<br />
1 Military Medical Academy, Belgrade, Yugoslavia<br />
2 School <strong>of</strong> Medicine, University <strong>of</strong> Belgrade, Department <strong>of</strong> Pharmacology, Belgrade, Yugoslavia<br />
3 Mediacl Faculty <strong>of</strong> Novi Sad, Department <strong>of</strong> Pharmacology, Novi Sad, Yugoslavia<br />
120. 120. OPTIMIZATION OPTIMIZATION OF OF CIPROFLOXACIN CIPROFLOXACIN CIPROFLOXACIN THERAPY THERAPY IN IN PATIENTS PATIENTS WITH WITH LOWER LOWER REPIRATORY REPIRATORY TRACT TRACT<br />
TRACT<br />
INFECTIONS INFECTIONS USING USING POPULATION POPULATION PHARMACOKINETIC PHARMACOKINETIC MODELLING<br />
MODELLING<br />
Wyska Wyska E., E., Cios Cios A AA.,<br />
A ., Szymura-Oleksiak Szymura-Oleksiak J., J., J., Mioduszewska- Mioduszewska- Mioduszewska- P PPawêzowska<br />
P awêzowska A AA.,<br />
A ., Grodzicki Grodzicki T TT.<br />
T<br />
Jagiellonian University, Department <strong>of</strong> Pharmacokinetics <strong>and</strong> Physical Pharmacy, Kraków, Pol<strong>and</strong><br />
121. 121. INFLUENCE INFLUENCE OF OF GENDER GENDER GENDER IN IN THE THE DISPOSITION DISPOSITION OF OF LOPERAMIDE<br />
LOPERAMIDE<br />
Laosa Laosa O OO.<br />
O 1 1 1 1 1 2 1<br />
, , Ochoa Ochoa D. D. , , Llanos Llanos L. L. , , Lubomirov Lubomirov R. R. , , Ramirez Ramirez E. E. , , Gomez Gomez E. E. , , , Carcas Carcas AJ. AJ.<br />
1 La Paz Hospital/ Autonoma University <strong>of</strong> Madrid, Farmacología Clínica, Madrid, Spain<br />
2 Normon Laboratories S.A., Madrid, Spain<br />
122. 122. MORPHINE MORPHINE RELEASE RELEASE GLUTAMATE GLUTAMATE THROUGH THROUGH AMPA AMPA RECEPTORS RECEPTORS RECEPTORS IN IN THE THE VTA:<br />
VTA:<br />
A A MICRODIALYSIS MICRODIALYSIS MICRODIALYSIS STUDY STUDY IN IN IN CONSCIOUS CONSCIOUS RATS RATS<br />
RATS<br />
Alaei Alaei H<br />
H<br />
University, Isfahan, Iran<br />
123. 123. 123. THE THE ROLE ROLE ROLE OF OF PROTEASE PROTEASE INHIBITORS INHIBITORS AND AND PROTEINASE-ACTIVATED PROTEINASE-ACTIVATED RECEPTORS-MODULATING<br />
RECEPTORS-MODULATING<br />
AGENTS AGENTS IN IN IN THE THE TREATMENT TREATMENT OF OF OF ALLERGIC ALLERGIC AND AND INFLAMMATORY INFLAMMATORY SKIN SKIN DISEASES<br />
DISEASES<br />
Bocheva Bocheva Bocheva G., G., G., Ilieva Ilieva Ilieva V VV.,<br />
V ., Boyadjieva Boyadjieva N.<br />
N.<br />
Medical University <strong>of</strong> S<strong>of</strong>ia, S<strong>of</strong>ia, Bulgaria<br />
124. 124. 124. TESTOSTERONE TESTOSTERONE ENANTHATE ENANTHATE INDUCES INDUCES THE THE EXPRESSION EXPRESSION OF OF ANDROGEN ANDROGEN RECEPTORS<br />
RECEPTORS<br />
IN IN RAT RAT HEPATIC HEPATIC CELLS<br />
CELLS<br />
Papamitsou apamitsou T TT.,<br />
T T.,<br />
., Dermentzopoulou Dermentzopoulou - - Theodoridou Theodoridou Theodoridou M., M., M., P PPapaioannidou<br />
P apaioannidou P PP.,<br />
P ., Barlagiannis Barlagiannis D., D., Manthos Manthos A AA.<br />
A<br />
Aristotelian University <strong>of</strong> Thessaloniki, Medical, Thessaloniki, Greece<br />
125. 125. APPLICATION APPLICATION OF OF ELECTROCHEMICAL ELECTROCHEMICAL DETECTION DETECTION FOR FOR PHARMACOKINETIC PHARMACOKINETIC STUDIES<br />
STUDIES<br />
Chmielewska Chmielewska Chmielewska A AA.,<br />
A ., K KKonieczna<br />
K Konieczna<br />
onieczna L., L., Plenis Plenis A AA.,<br />
A ., Lamparczyk Lamparczyk H.<br />
H.<br />
Medical University <strong>of</strong> Gdañsk, Pharmaceutical Chemistry, Gdañsk, Pol<strong>and</strong><br />
126. 126. 126. EFFECT EFFECT OF OF TESTOSTERONE TESTOSTERONE ENANTHATE ENANTHATE ON ON THE THE ULTRASTRUCTURE ULTRASTRUCTURE ULTRASTRUCTURE OF OF RAT RAT HEPATIC HEPATIC CELLS<br />
CELLS<br />
Papamitsou apamitsou T TT.<br />
T 1 1 2 1 1 , , Dermentzopoulou-<br />
Dermentzopoulou-Theodoridou Dermentzopoulou- Theodoridou M. M. , , P PPapaioannidou<br />
P apaioannidou PP<br />
P. P , , Barlagiannis Barlagiannis D. D. , , Manthos Manthos A AA.<br />
A 1<br />
1 Aristotelian University <strong>of</strong> Thessaloniki, Medical Department, Thessaloniki, Greece<br />
2 Aristotelian University <strong>of</strong> Thessaloniki, Thessaloniki, Greece<br />
479. 479. DIFERENCES DIFERENCES BETWEEN BETWEEN CISPLATIN- CISPLATIN- AND AND AND 5-FLUOROURACIL 5-FLUOROURACIL INDUCED INDUCED ANEMIA ANEMIA ANEMIA AND<br />
AND<br />
THE THE ROLE ROLE ROLE OF OF ENDOGENOUS ENDOGENOUS ERYTHROPOIETIN ERYTHROPOIETIN IN IN THEIR THEIR DEVELOPMENT<br />
DEVELOPMENT<br />
Zafirov Zafirov D. D. D. 1 2 3 3 3 3<br />
, , , Ristovski Ristovski M. M. , , Labacevski Labacevski Labacevski N. N. , , Balkanov Balkanov T TT.<br />
T , , Milosevski Milosevski P PP.<br />
P , , P PPetrov<br />
PP<br />
etrov S. S.<br />
1 Medical faculty, Skopje<br />
2 Medical Faculty, Pathology, Skopje<br />
3 Medical Faculty, Pharmacology, Skopje<br />
POSTER POSTER SESSION SESSION SESSION 3<br />
3<br />
127. 127. INTAKE INTAKE OF OF HERBAL HERBAL PREPARATIONS PREPARATIONS AND AND DIETARY DIETARY SUPPLEMENTS SUPPLEMENTS BEFORE BEFORE BEFORE PERIOPERATIVE<br />
PERIOPERATIVE<br />
PERIOPERATIVE<br />
ANESTHESIA ANESTHESIA – – RISK RISK OR OR BENEFIT?<br />
BENEFIT?<br />
O¿arowski O¿arowski M., M., Mrozikiewicz Mrozikiewicz Mrozikiewicz PM.<br />
PM.<br />
Research Institute <strong>of</strong> Medicinal Plants, Poznañ, Pol<strong>and</strong><br />
– – –
128. 128. 128. ACTIVITIES ACTIVITIES OF OF OF THE THE INTERNATIONAL INTERNATIONAL SCIENTIFIC SCIENTIFIC NETWORK NETWORK “INTERACTIONS “INTERACTIONS BETWEEN<br />
BETWEEN<br />
HERBAL HERBAL AND AND SYNTHETIC SYNTHETIC DRUGS DRUGS DRUGS - - ADVANTAGES ADVANTAGES AND AND RISKS”<br />
RISKS”<br />
Krajewska-P<br />
Krajewska-Patan Krajewska-P atan AA<br />
A. A 1 2 1 1<br />
, , , Bobkiewicz-K<br />
Bobkiewicz-Kozlowska Bobkiewicz-K ozlowska T TT.<br />
T , , Ozarowski Ozarowski M. M. , , Mrozikiewicz Mrozikiewicz PM. PM.<br />
1 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
2 Poznan University <strong>of</strong> Medical Sciences, Department <strong>of</strong> Pharmacology, Poznan, Pol<strong>and</strong><br />
129. 129. PROTECTIVE PROTECTIVE EFFECT EFFECT OF OF VOLATILE VOLATILE OIL, OIL, ALCOHOLIC ALCOHOLIC AND AND AND AQUEOUS AQUEOUS EXTRACTS EXTRACTS OF OF ORIGANUM<br />
ORIGANUM<br />
ORIGANUM<br />
MAJORANA MAJORANA MAJORANA ON ON LEAD LEAD ACETATE ACETATE TOXICITY TOXICITY IN IN MICE MICE<br />
MICE<br />
Elashmawy Elashmawy I. I. I. 1 2 2 2<br />
, , El-Ashmawy El-Ashmawy I. I. , , , El-Nahas El-Nahas A AA.<br />
A , , Salama Salama O OO.<br />
O<br />
1 Fac. Vet Med. Alex<strong>and</strong>ria Univ., Edfina, Rossett Line, Behera<br />
2 Egyptian Pharmacology, Egypt<br />
130. 130. COMPARISON COMPARISON BETWEEN BETWEEN THE THE PLANT PLANT STEROL STEROL CONTENT CONTENT OF OF NIGELLA NIGELLA SATIVA SATIVA OIL OIL AND<br />
AND<br />
OLIVE OLIVE OIL OIL SOLD SOLD IN IN LIBYAN LIBYAN LOCAL LOCAL MARKET<br />
MARKET<br />
Agnan Agnan MM., MM., Alkilani Alkilani MK.<br />
MK.<br />
Sakr Africia University , Nalut, Libya<br />
131. 131. PROBIOTICS PROBIOTICS IN IN COMPOSITION COMPOSITION COMPOSITION WITH WITH HERBS HERBS – – NEW NEW POSSIBILITIES?<br />
POSSIBILITIES?<br />
POSSIBILITIES?<br />
Furtak urtak M., M., Mrozikiewicz Mrozikiewicz PM., PM., Mœcisz Mœcisz Mœcisz A AA.<br />
A<br />
Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
132. 132. ANTIMICROBIAL ANTIMICROBIAL ACTIVITY ACTIVITY OF OF RHODIOLA RHODIOLA ROSEA ROSEA EXTRACTS<br />
EXTRACTS<br />
Krajewska-P<br />
Krajewska-Patan Krajewska-P atan A AA.<br />
A 1 1 1 1 1 2 , , K KKedzia<br />
K edzia B. B. , , Dreger Dreger M. M. , , Mscisz Mscisz A AA.<br />
A , , Buchwald Buchwald W WW.<br />
W , , F FFurmanowa<br />
F urmanowa M. M. , , Mrozikiewicz Mrozikiewicz Mrozikiewicz P PP.M.<br />
P .M.<br />
1 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
2 Medical University <strong>of</strong> Warsaw, Department <strong>of</strong> Biology <strong>and</strong> Pharmaceutical Botany, Warsaw, Pol<strong>and</strong><br />
133. 133. 133. THE THE INFLUENCE INFLUENCE OF OF DIFFERENT DIFFERENT RHODIOLA RHODIOLA EXTRACTS EXTRACTS EXTRACTS ON ON MURINE MURINE MURINE TUMOR TUMOR CELLS CELLS CELLS ANGIOGENIC ANGIOGENIC ACTIVITY<br />
ACTIVITY<br />
Skopiñska-Ró¿ewska Skopiñska-Ró¿ewska E. E. 1 2 3 4 2 , , , Mœcisz Mœcisz Mœcisz AA<br />
A. AA<br />
, , , Sommer Sommer E., E., E., Skopiñski Skopiñski Skopiñski P PP.<br />
P , , F FFurmanowa<br />
F urmanowa M. M. , , Mrozikiewicz Mrozikiewicz Mrozikiewicz PM. PM. PM. .<br />
1 Department <strong>of</strong> Pathology, Medical University in Warsaw, Warsaw, Pol<strong>and</strong><br />
2 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
3 Department <strong>of</strong> Histology&Embryology, Medical University in Warsaw, Warsaw, Pol<strong>and</strong><br />
4 Department <strong>of</strong> Biology <strong>and</strong> Pharmaceutical Botany Medical University, Warsaw, Pol<strong>and</strong>.<br />
134. 134. HYPOLIPIDEMIC HYPOLIPIDEMIC EFFECT EFFECT OF OF VOLATILE VOLATILE OIL, OIL, ALCOHOLIC ALCOHOLIC AND AND AQUEOUS AQUEOUS EXTRACTS<br />
EXTRACTS<br />
OF OF ORIGANUM ORIGANUM MAJORANA MAJORANA IN IN HYPERCHOLESTEROLEMIC HYPERCHOLESTEROLEMIC RATS<br />
RATS<br />
Elashmawy Elashmawy I. I. 1 2<br />
, , , Salama Salama O OO.<br />
O<br />
1 Fac. Vet Med. Alex<strong>and</strong>ria University, Edfina, Rossett Line, Behera<br />
2 OSAMA, Pharmacology, Alex<strong>and</strong>ria, Egypt<br />
135. 135. BROMELAIN BROMELAIN BROMELAIN IMPROVES IMPROVES INTESTINAL INTESTINAL PROPULSIVE PROPULSIVE DYSMOTILITY DYSMOTILITY OF OF POSTOPERATIVE POSTOPERATIVE ILEUS ILEUS IN IN RATS: RATS:<br />
RATS:<br />
INHIBITION INHIBITION OF OF INDUCIBLE INDUCIBLE NITRIC NITRIC OXIDE OXIDE OXIDE SYNTHASE SYNTHASE AND AND NUCLEAR NUCLEAR FACTOR-KB FACTOR-KB ACTIVATION<br />
ACTIVATION<br />
Wen en en S. S. 1 2 2 3 2 2<br />
, , Huang Huang TH. TH. , , K KKota<br />
K ota BP BP.2, BP .2, Li Li GQ. GQ. , , Y YYamahara<br />
Y amahara J. J. , , Roufogalis Roufogalis BD. BD. , , Li Li Y YY.<br />
Y<br />
1 University <strong>of</strong> Technology, Sydney, Department <strong>of</strong> Health Science, Sydney, Australia<br />
2 The University <strong>of</strong> Sydney, Faculty <strong>of</strong> Pharmacy, Sydney, Australia<br />
3 Pharmafood Institute, Japan, Kyoto, Japan<br />
137. 137. 137. SOME SOME BEHAVIORAL BEHAVIORAL ASPECTS ASPECTS OF OF RHODIOLA RHODIOLA RHODIOLA ROSEA ROSEA EXTRACTS EXTRACTS EXTRACTS ACTIVITY ACTIVITY IN IN RATS<br />
RATS<br />
Mikolajczak Mikolajczak Mikolajczak PL. PL. PL. 1,2 , , , Okulicz-K Okulicz-K Okulicz-Kozaryn Okulicz-K ozaryn I. I. I. 1,2 , , Bobkiewicz-K<br />
Bobkiewicz-Kozlowska Bobkiewicz-K<br />
Bobkiewicz-Kozlowska<br />
ozlowska T TT.<br />
T 1 2 2 , , Buchwald Buchwald Buchwald W WW.<br />
W , , , Krajewska-P<br />
Krajewska-P<br />
Krajewska-Patan Krajewska-P atan A AA.<br />
A , , Lowicka<br />
Lowicka<br />
A. 2 3 1 1 2 2 2 , , F FFurmanowa<br />
F urmanowa M. M. , , F FForjasz-Grus<br />
F Forjasz-Grus<br />
orjasz-Grus R. R. , , KK<br />
Korzeniowska-Jasiewicz KK<br />
orzeniowska-Jasiewicz E. E. , , Dreger Dreger M. M. , , PP<br />
Paukszta-Gorska PP<br />
aukszta-Gorska M. M. , , , Mscisz Mscisz A AA.<br />
A ,<br />
Mrozikiewicz Mrozikiewicz PM. PM. 2<br />
1 Poznañ University <strong>of</strong> Medical Sciences, Department <strong>of</strong> Pharmacology, Poznan, Pol<strong>and</strong><br />
2 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
3 Medical University <strong>of</strong> Warsaw, Department <strong>of</strong> Biology <strong>and</strong> Pharmaceutical Botany, Warsaw, Pol<strong>and</strong><br />
138. 138. INTERACTION INTERACTION OF OF INFUSIONS INFUSIONS OF OF TWO TWO HEMP HEMP HEMP GENOTYPES GENOTYPES GROWN GROWN GROWN UNDER UNDER THE THE SAME<br />
SAME<br />
CLIMATIC CLIMATIC CONDITIONS CONDITIONS WITH WITH CENTRAL CENTRAL ACTION ACTION DRUGS<br />
DRUGS<br />
Horvat Horvat O OO.<br />
O 1 2 2 3<br />
, , Jakovljevic Jakovljevic V VV.<br />
V , , Sabo Sabo Sabo A AA.<br />
A , , Berenji Berenji J. J.<br />
1 Faculty <strong>of</strong> Medicine, Novi Sad, Yugoslavia<br />
2 Faculty <strong>of</strong> Medicine, Pharmacology <strong>and</strong> Toxicology, Novi Sad, Yugoslavia<br />
3 Institute <strong>of</strong> Field <strong>and</strong> Vegetable Crops, Novi Sad, Yugoslavia<br />
– – –<br />
.M. 1
139. 139. 139. INFLUENCE INFLUENCE OF OF VARIOUS VARIOUS CANNABINOIDES CANNABINOIDES IN IN TWO TWO GENOTYPES GENOTYPES OF OF OF HEMP HEMP ON ON ALIMENTARY ALIMENTARY TRACT<br />
TRACT<br />
Vukmirovic ukmirovic ukmirovic S., S., Sabo Sabo Sabo A AA.,<br />
A ., Horvat Horvat O OO.<br />
O<br />
Medical Faculty <strong>of</strong> Novi Sad, Novi Sad, Yugoslavia<br />
140. 140. THE THE THE CHRONIC CHRONIC EFFECT EFFECT OF OF KOMBUCH KOMBUCH TEA TEA CONSUMPTION CONSUMPTION ON ON ON WEIGHT WEIGHT LOSS LOSS IN IN DIABETIC DIABETIC DIABETIC RATS<br />
RATS<br />
Morshedi Morshedi A AA.,<br />
A ., Dashti Dashti MH., MH., Salami Salami AA AA. AA<br />
Shahid Sadughi Medical University, Physiology, Yazd, Iran<br />
141. 141. PHYTOCHEMICAL PHYTOCHEMICAL STUDY STUDY OF OF RHODIOLA RHODIOLA ROSEA, ROSEA, RHODIOLA RHODIOLA QUADRIFIDA<br />
QUADRIFIDA<br />
AND AND RHODIOLA RHODIOLA KIRILOWII KIRILOWII EXTRACTS EXTRACTS<br />
EXTRACTS<br />
Mœcisz Mœcisz Mœcisz AA<br />
A. AA<br />
1 1 1 1 2 , , Mielcarek Mielcarek S. S. , , Buchwald Buchwald W WW.<br />
WW<br />
, , Krajewska-P<br />
Krajewska-Patan Krajewska-P atan AA<br />
A. AA<br />
,.F ,.Furmanowa ,.F urmanowa M. M. M. ,<br />
Skopinska Skopinska Ró¿ewska Ró¿ewska E. E. 3 1 1<br />
, , Luczkowska Luczkowska T TT.<br />
TT<br />
, , Mrozikiewicz Mrozikiewicz PM. PM.<br />
1 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
2 Medical University <strong>of</strong> Warsaw, Department <strong>of</strong> Biology <strong>and</strong> Pharmaceutical Botany, Warszawa, Pol<strong>and</strong><br />
3 Medical University <strong>of</strong> Warsaw, Department <strong>of</strong> Pathology, Warszawa, Pol<strong>and</strong><br />
142. 142. STUDIES STUDIES ON ON MECHANICAL MECHANICAL EFFECT EFFECT OF OF CARUM CARUM COPTICUM COPTICUM BY BY ASSESSING ASSESSING INTESTINAL INTESTINAL MOTILITY MOTILITY IN IN RAT<br />
RAT<br />
Hejazian Hejazian Hejazian SH. SH. 1 2<br />
, , , Mahdavi Mahdavi M. M.<br />
1 Shahid Sadughi Medical University, ? Yazd, Iran<br />
2 Shahid Sadughi Medical University, Physiology, Yazd, Iran<br />
143. 143. ANTIDIABETIC ANTIDIABETIC EFFECT EFFECT OF OF ALCOHOLIC ALCOHOLIC EXTRACT EXTRACT OF OF LEAF LEAF OF OF NETTLE NETTLE NETTLE (URTICA (URTICA DIOICA DIOICA L.) L.)<br />
L.)<br />
IN IN STREPTOZOCIN-INDUCED STREPTOZOCIN-INDUCED STREPTOZOCIN-INDUCED DIABETIC DIABETIC RATS.<br />
RATS.<br />
Hadjikhani Hadjikhani R., R., Solati Solati J. J.<br />
J.<br />
Karaj Islamic Azad University, Karaj, Iran<br />
144. 144. ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL EFFECT EFFECT OF OF ZATARIA ZATARIA ZATARIA MULTIFLORA MULTIFLORA ON ON 3 3 BACTERIAL BACTERIAL SEPECIESES SEPECIESES CAUSE CAUSE<br />
CAUSE<br />
GASTEROENTRITIS<br />
GASTEROENTRITIS<br />
Vahidi ahidi ahidi Mehrjardi Mehrjardi AA<br />
A., AA<br />
., Bagher Bagher Khalili Khalili M., M., M., Shojaii Shojaii Shojaii N. N.<br />
N.<br />
Shahid Sadughi Medical University, Yazd, Iran<br />
145. 145. THE THE THE CHOSEN CHOSEN BEHAVIORAL BEHAVIORAL ASPECTS ASPECTS ASPECTS OF OF OF LEPIDIUM LEPIDIUM PERUVIANUM PERUVIANUM (MACA) (MACA) ACTIVITY<br />
ACTIVITY<br />
ON ON OVARIECTOMIZED OVARIECTOMIZED OVARIECTOMIZED RATS<br />
RATS<br />
£owicka £owicka A A A1<br />
2 1,2 1,2<br />
1,2 1,2<br />
1 ., ., Bobkiewicz-K<br />
Bobkiewicz-K<br />
Bobkiewicz-Koz³owska Bobkiewicz-K<br />
Bobkiewicz-Koz³owska<br />
oz³owska TT<br />
T. T , , Miko³ajczak Miko³ajczak PL. PL. PL. , , , Okulicz-K Okulicz-Kozaryn Okulicz-K ozaryn I. I. , , , Mœcisz Mœcisz AA<br />
A. AA<br />
,<br />
Mrozikiewicz Mrozikiewicz PM. PM. 1<br />
1 Research Institute <strong>of</strong> Medicinal Plants, Poznañ<br />
2 Department <strong>of</strong> Pharmacology, Poznañ University <strong>of</strong> Medical Sciences<br />
146. 146. EFFECTS EFFECTS OF OF ALCOHOLIC ALCOHOLIC EXTRACT EXTRACT OF OF WALNUT WALNUT (JUGLANS (JUGLANS REGIA REGIA L.) L.) L.) SEPTUM SEPTUM ON ON SERUM SERUM SERUM GLUCOSE,<br />
GLUCOSE,<br />
INSULIN INSULIN AND AND ACTIVITIES ACTIVITIES OF OF AMINOTRANSFERASE AMINOTRANSFERASE ENZYMES ENZYMES IN IN STREPTOZOCIN-INDUCED<br />
STREPTOZOCIN-INDUCED<br />
DIABETIC DIABETIC RATS.<br />
RATS.<br />
Solati Solati J. J. 1 2 3<br />
, , , Oryan Oryan S. S. , , Hadjikhani Hadjikhani R. R.<br />
1 Karaj Azad Islamic University, Microbiology, Karaj, Iran<br />
2 Tehran Teacher Traning University, Biology, Tehran, Iran<br />
3 Karaj Islamic Azad University, Microbiology, Karaj, Iran<br />
147. 147. THE THE APPLICATION APPLICATION APPLICATION OF OF MOLECULAR MOLECULAR MOLECULAR MARKERS MARKERS TO TO ANALYSIS ANALYSIS OF OF GENETIC GENETIC VARIABILITY<br />
VARIABILITY<br />
OF OF PLATYCODON PLATYCODON GRANDIFLORUM GRANDIFLORUM (JACQ.) (JACQ.) A. A. A. DC. DC. PLANTS<br />
PLANTS<br />
Mrozikiewicz Mrozikiewicz PM., PM., Buchwald Buchwald Buchwald W WW.,<br />
WW<br />
., Krajewska-P<br />
Krajewska-Patan Krajewska-P atan A AA.,<br />
A ., Z<strong>and</strong>ecka-Dziubak Z<strong>and</strong>ecka-Dziubak J., J., T TTomaszewska<br />
T omaszewska M., M., M., Dudzinska-Bajorek Dudzinska-Bajorek Dudzinska-Bajorek B.<br />
B.<br />
Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
148. 148. BLOOD BLOOD LEAD LEAD LEVELS LEVELS AND AND RELATION RELATION TO TO BODY BODY BODY IRON IRON IRON QUALITY QUALITY IN IN CHILDREN<br />
CHILDREN<br />
Ebadi Ebadi Ebadi AG. AG.<br />
AG.<br />
Islamic Azad University <strong>of</strong> Sari, Sari, Iran<br />
149. 149. INFLUENCE INFLUENCE OF OF THE THE NATURAL NATURAL PRODUCT PRODUCT STEVIOSIDE STEVIOSIDE ON ON THE THE HYPOGLYCAEMIC HYPOGLYCAEMIC EFFECT EFFECT OF OF GLICLAZIDE<br />
GLICLAZIDE<br />
GLICLAZIDE<br />
Raskovic Raskovic A AA.,<br />
A ., Jakovljevic Jakovljevic V VV.,<br />
V ., Mikov Mikov Mikov M.<br />
M.<br />
Medical Faculty <strong>of</strong> Novi Sad, Novi Sad, Yugoslavia<br />
– – –
150. 150. 150. COASSUMPTION COASSUMPTION OF OF HERBAL HERBAL AND AND CONVENTIONAL CONVENTIONAL MEDICINES: MEDICINES: IMPLICATIONS IMPLICATIONS FOR FOR SAFETY<br />
SAFETY<br />
Cuzzolin Cuzzolin L., L., Zaffani Zaffani S., S., Benoni Benoni G. G.<br />
G.<br />
University <strong>of</strong> Verona, Dept. Medicine & Public Health - Section <strong>of</strong> Pharmacology, Verona, Italy<br />
151. 151. THE THE EFFECT EFFECT OF OF DEVELOPMENT DEVELOPMENT STAGE STAGE STAGE OF OF EPILOBIUM EPILOBIUM ANGUSTIFOLIUM ANGUSTIFOLIUM ANGUSTIFOLIUM L. L. ON ON ON THE THE CONTENT<br />
CONTENT<br />
OF OF BIOLOGICAL BIOLOGICAL ACTIVE ACTIVE SUBSTANCES<br />
SUBSTANCES<br />
SUBSTANCES<br />
Mrozikiewicz Mrozikiewicz PM., PM., Otta Otta H., H., H., Buchwald Buchwald W WW.,<br />
W ., Luczkowska Luczkowska T TT.,<br />
T ., W WWojciechowska<br />
W ojciechowska S., S., S., Mscisz Mscisz AA<br />
A. AA<br />
Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
152. 152. HERBAL HERBAL PRODUCTS: PRODUCTS: BEHAVIOURS BEHAVIOURS AND AND BELIEFS BELIEFS AMONG AMONG ITALIAN ITALIAN WOMEN<br />
WOMEN<br />
Cuzzolin Cuzzolin L., L., Zaffani Zaffani S., S., Benoni Benoni G. G.<br />
G.<br />
University <strong>of</strong> Verona, Dept. Medicine & Public Health - Section <strong>of</strong> Pharmacology, Verona, Italy<br />
153. 153. MIRAZID; MIRAZID; A A NEW NEW SCHISTOSOMICIDAL SCHISTOSOMICIDAL AGENT AGENT DERIVED DERIVED FROM FROM MYRRH: MYRRH:<br />
MYRRH:<br />
EVALUATION EVALUATION OF OF ITS ITS HYPOLYCEMIC HYPOLYCEMIC ACTION ACTION IN IN STREPTOZOTOCIN-DIABETIC STREPTOZOTOCIN-DIABETIC RATS<br />
RATS<br />
Elashmawy Elashmawy I., I., Elashmawy Elashmawy I., I., Salama Salama O OO.<br />
O<br />
Fac. Vet Med. Alex<strong>and</strong>ria Univ., Edfina, Rossett Line, Behera,Egypt<br />
154. 154. ALOE ALOE ABORESCENS ABORESCENS IN IN THE THE TREATMENT TREATMENT OF OF UPPER UPPER RESPIRATORY RESPIRATORY TRACT TRACT INFECTIONS INFECTIONS -<br />
-<br />
RESULTS RESULTS OF OF A A POST-MARKETING POST-MARKETING POST-MARKETING SURVEILLANCE SURVEILLANCE STUDY<br />
STUDY<br />
Sievers Sievers H., H., Lehnfeld Lehnfeld R.<br />
R.<br />
PhytoLab GmbH & Co. KG, Vestenbergsgreuth, Germany<br />
155. PHARMACOVIGILANCE OF HERBAL MEDICINAL PRODUCTS - ADEQUATE HANDLING<br />
AND REPORTING OF LITERATURE CASES<br />
Sievers Sievers H. H. 1 1 2<br />
, , Lehnfeld Lehnfeld R. R. R. , , , Nowak Nowak Nowak K. K.<br />
1 PhytoLab GmbH & Co. KG, Vestenbergsgreuth, Germany<br />
2 Europlant PhytoPharm Sp. z.o.o., Poznan, Pol<strong>and</strong><br />
156. 156. 156. THE THE WOUND-HEALING WOUND-HEALING EFFECT EFFECT OF OF HEDERA HEDERA HEDERA HELIX HELIX OINTMENT<br />
OINTMENT<br />
Becic Becic F FF.<br />
F 1 1 1 1 1 2<br />
, , Mulabegoviæ Mulabegoviæ Mulabegoviæ N. N. , , , Kapiæ Kapiæ E. E. , , KK<br />
Kusturica KK<br />
usturica J. J. , , TT<br />
Todiæ TT<br />
odiæ M. M. , , , Prasoviæ Prasoviæ Prasoviæ S. S. S.<br />
1 Faculty <strong>of</strong> Medicine, Institute <strong>of</strong> Pharmacology, Clinical Pharmacology <strong>and</strong> Toxicology, Sarajevo, Yugoslavia<br />
2 Faculty <strong>of</strong> Veterinary Medicine, Institute <strong>of</strong> Pathology, Sarajevo, Yugoslavia<br />
158. 158. INFLUENCE INFLUENCE AMARANTH AMARANTH INDUCED INDUCED GASTROPROTECTION GASTROPROTECTION AND AND ANTIULCER ANTIULCER ACTION<br />
ACTION<br />
ON ON GASTRIC GASTRIC MUCOSAL MUCOSAL MUCOSAL REPAIR<br />
REPAIR<br />
Zayachkivska Zayachkivska O OO.<br />
O<br />
Lviv National Medical University, Lviv, Ukraine<br />
159. 159. THE THE EFFECT EFFECT EFFECT OF OF TIME TIME CROP CROP CROP OF OF RHODIOLA RHODIOLA KIRILOWII KIRILOWII AND AND RHODIOLA RHODIOLA ROSEA ROSEA ROSEA ROOTS<br />
ROOTS<br />
ON ON THE THE CONTENT CONTENT OF OF PHARMACOLOGICAL PHARMACOLOGICAL ACTIVE ACTIVE COMPOUNDS<br />
COMPOUNDS<br />
Buchwald Buchwald W WW.<br />
W . 1 1 1 2 1 1 1<br />
, , , Krajewska-P Krajewska-Patan Krajewska-P atan A AA.<br />
A , , Przybylak Przybylak Przybylak J. J. , , FF<br />
Furmanowa F urmanowa M. M. , , , Luczkowska Luczkowska T TT.<br />
TT<br />
, , Mscisz Mscisz A AA.<br />
A , , Mrozikiewicz Mrozikiewicz PM. PM. PM.<br />
1 Research Institute <strong>of</strong> Medicinal Plants, Poznan, Pol<strong>and</strong><br />
2 Medical University <strong>of</strong> Warsaw, Department <strong>of</strong> Biology <strong>and</strong> Pharmaceutical Botany, Warszawa, Pol<strong>and</strong><br />
160. 160. ACUTE ACUTE HEPATITIS HEPATITIS FROM FROM A A HERBAL HERBAL HERBAL REMEDY REMEDY FOR FOR WEIGHT WEIGHT LOSS, LOSS, BOUGHT BOUGHT BOUGHT OVER OVER OVER THE THE INTERNET INTERNET<br />
INTERNET<br />
Boettiger Boettiger YY<br />
Y. YY<br />
1 1 2<br />
, , Jansson Jansson A AA.<br />
A , , Arneborn Arneborn P PP.<br />
P<br />
1 Laboratory Medicine, Karolinska Institut, Stockholm, Sweden<br />
2 Oerebro University Hospital, Dept <strong>of</strong> infectious diseases, Oerebro, Sweden<br />
161. 161. ANTICOCCIDIAL ANTICOCCIDIAL EFFECTS EFFECTS OF OF THE THE THE ARTEMISIA ARTEMISIA SIEBERI SIEBERI IN IN BROILER BROILER CHICKENS<br />
CHICKENS<br />
Arab Arab Arab H., H., Rahbari Rahbari Rahbari S., S., S., Rassouli Rassouli A AA.,<br />
A ., Moslemi Moslemi MH.<br />
MH.<br />
Faculty <strong>of</strong> Veterinary Medicin, Tehran University, Tehran, Iran<br />
162. 162. REGULATION REGULATION OF OF GENE GENE EXPRESSION EXPRESSION EXPRESSION BY BY THE THE HERBAL HERBAL ANTIDEPRESSANT ANTIDEPRESSANT ST. ST. JOHN'S JOHN'S WORT<br />
WORT<br />
AND AND ITS ITS CONSTITUENT CONSTITUENT HYPERFORIN<br />
HYPERFORIN<br />
HYPERFORIN<br />
Krusekopf Krusekopf S. S. 1 2 , , Roots Roots I. I.<br />
1 CENiMED, Center <strong>for</strong> Individualized Medicine, Berlin, Germany<br />
2 Humboldt University <strong>of</strong> Berlin, Institute <strong>of</strong> Clinical Pharmacology, Campus Charité Mitte,<br />
Charité University Medical Center, Berlin, Germany<br />
– – –
Change language